Prescription attached:-

đŠē LIPU MED â COMPLETE CLINICAL CASE REVIEW
Prescription Analysis | Clinical Diagnosis | Evidence-Based Management | MedEx Bangladesh | 10 Clinical Decision-Making Modules
đ§ PROPOSED WEBSITE PUBLICATION TITLE
TC(1485).(02). Dermatology Department Case No (106): Undifferentiated Genital Ulcer Disease with Associated Skin Rash and Generalized Weakness â Suspected Syphilis versus Genital Herpes; Possible Secondary Bacterial Infection â Clinical Diagnosis, Prescription Safety Review and Guideline-Based Management (1 Prescription + 0 Reports + 0 Clinical Images)
āĻŦāĻžāĻāϞāĻž āĻļāĻŋāϰā§āύāĻžāĻŽ
āϝā§āύāĻžāĻā§āĻā§ āĻāĻž, āĻļāϰā§āϰ⧠āϰâā§āϝāĻžāĻļ āĻ āĻĻā§āϰā§āĻŦāϞāϤāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻā§āύāĻŋāĻāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ āĻāĻŦāĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§, āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĻŦā§āϝāĻŦāϏā§āĻĨāĻžāϰ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻžāĨ¤
Department: Dermatology & Venereology â āĻāϰā§āĻŽ āĻ āϝā§āύāϰā§āĻ āĻŦāĻŋāĻāĻžāĻāĨ¤
DCS: 02
Proposed TC: 1485
Proposed Department Case Number: 106
Case type: Prescription-based clinical assessment.
Evidence available: One prescription. No investigation results or clinical photographs.
Diagnostic certainty: Provisional / Working Diagnosis.
Confidence: 0.99 for documented clinical syndrome; etiological diagnosis remains unconfirmed.
đ§ SECTION 1. ORIGINAL PRESCRIPTION INFORMATION
1.1 Patient Information â āϰā§āĻā§āϰ āĻĒāϰāĻŋāĻāĻŋāϤāĻŋ
| Parameter | Original Information | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Confidence |
|---|---|---|---|
| Patient Name | Nazem Ali | āύāĻžāĻā§āĻŽ āĻāϞ⧠| 0.99 |
| Sex | Male | āĻĒā§āϰā§āώ | 0.99 |
| Age | 52 years | ā§Ģ⧍ āĻŦāĻāϰ | 0.99 |
| Weight | 65 kg | ā§Ŧā§Ģ āĻā§āĻāĻŋ | 0.99 |
| Consultation Date | 20 October 2026 | ⧍ā§Ļ āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ | 0.99 |
| Prescription Type | Outpatient prescription | āĻŦāĻšāĻŋāϰā§āĻŦāĻŋāĻāĻžāĻā§āϰ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ | 0.95 |
| Physician’s Dx | Not documented | āĻāĻŋāĻāĻŋā§āϏāĻ āϰā§āĻā§āϰ āύāĻžāĻŽ āϞā§āĻā§āύāύāĻŋ | 0.99 |
| Investigation Results | Not attached | āĻĒāϰā§āĻā§āώāĻžāϰ āϰāĻŋāĻĒā§āϰā§āĻ āĻĻā§āĻā§āĻž āĻšā§āύāĻŋ | 0.99 |
1.2 Original Prescribing Doctor â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϤāĻĨā§āϝ
Name: Dr. Mamunur Rashid â āĻĄāĻžāĻ āĻŽāĻžāĻŽā§āύā§āϰ āϰāĻļā§āĻĻāĨ¤
Visible qualifications: MBBS (Dhaka), BCS (Health)āĨ¤ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϰāĻ āĻāĻŋāĻā§ āĻĒā§āϰāĻļāĻŋāĻā§āώāĻŖāϏāĻāĻā§āϰāĻžāύā§āϤ āϤāĻĨā§āϝ āϰā§ā§āĻā§, āϤāĻŦā§ āϏāĻŦāĻā§āϞ⧠āϏāĻŽā§āĻĒā§āϰā§āĻŖ āϏā§āĻĒāώā§āĻ āύā§āĨ¤
Designation: Medical Officer â āĻŽā§āĻĄāĻŋāĻā§āϞ āĻ āĻĢāĻŋāϏāĻžāϰāĨ¤
Institution: Bauphal Upazila Health Complex, Bauphal, Patuakhali â āĻŦāĻžāĻāĻĢāϞ āĻāĻĒāĻā§āϞāĻž āϏā§āĻŦāĻžāϏā§āĻĨā§āϝ āĻāĻŽāĻĒā§āϞā§āĻā§āϏ, āĻŦāĻžāĻāĻĢāϞ, āĻĒāĻā§ā§āĻžāĻāĻžāϞā§āĨ¤
Chamber: BOGA DIGITAL DIAGNOSTIC CENTER â āĻŦāĻāĻž āĻĄāĻŋāĻāĻŋāĻāĻžāϞ āĻĄāĻžā§āĻžāĻāύāϏā§āĻāĻŋāĻ āϏā§āύā§āĻāĻžāϰ, āĻŦāĻāĻž āĻŦāĻžāĻāĻžāϰ, āĻŦāĻžāĻāĻĢāϞ, āĻĒāĻā§ā§āĻžāĻāĻžāϞā§āĨ¤
BMDC registration: Printed on the original prescription; exact digits should be confirmed from the source before transcription.
Confidence: 0.98 for clearly legible information.
Publication privacy statement: āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϰā§āĻā§ āĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻžāĻŽ āĻāĻ āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻžā§ āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āϰāĻžāĻāĻž āĻšā§ā§āĻā§āĨ¤ āϰā§āĻā§āϰ āϝā§āύāϏā§āĻŦāĻžāϏā§āĻĨā§āϝāϏāĻāĻā§āϰāĻžāύā§āϤ āϤāĻĨā§āϝ āĻāĻŦāĻ āĻĒāϰāĻŋāĻā§ āĻāύā§āĻŽā§āĻā§āϤ āĻā§ā§āĻŦāϏāĻžāĻāĻā§ āĻĒā§āϰāĻāĻžāĻļā§āϰ āĻāĻā§ āϝāĻĨāĻžāϝāĻĨ āϞāĻŋāĻāĻŋāϤ āϏāĻŽā§āĻŽāϤāĻŋ āĻĒā§āϰā§ā§āĻāύāĨ¤
đ§ SECTION 2. CHIEF COMPLAINTS â C/C
C/C means Chief Complaints â āϰā§āĻā§āϰ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻāĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϤāĻŋāύāĻāĻŋ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ āϞāĻŋāĻā§āĻā§āύāĨ¤
| No. | Original C/C | Clinical Meaning | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Confidence |
|---|---|---|---|---|
| 1 | G. Weakness | Generalized weakness | āϏāĻžāϰā§āĻŦāĻŋāĻ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĻā§āϰā§āĻŦāϞāϤāĻž | 0.98 |
| 2 | Ulcer on private part | Genital ulceration | āϝā§āύāĻžāĻā§āĻā§ āĻāĻž | 0.99 |
| 3 | Skin rash | Cutaneous rash | āĻļāϰā§āϰā§āϰ āϤā§āĻŦāĻā§ āϰâā§āϝāĻžāĻļ āĻŦāĻž āĻĢā§āϏāĻā§ā§āĻŋ | 0.99 |
2.1 Generalized Weakness â āϏāĻžāϰā§āĻŦāĻŋāĻ āĻĻā§āϰā§āĻŦāϞāϤāĻž
Definition: A subjective feeling of reduced physical energy or strength.
āĻŦāĻžāĻāϞāĻž: āĻļāϰā§āϰā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻļāĻā§āϤāĻŋ āĻŦāĻž āĻāϰā§āĻŽāĻā§āώāĻŽāϤāĻž āĻāĻŽā§ āϝāĻžāĻā§āĻžāϰ āĻ āύā§āĻā§āϤāĻŋāĨ¤
Possible etiology: Anaemia, infection, malnutrition, endocrine disease, diabetes and various systemic illnesses.
āĻŦāĻžāĻāϞāĻž: āϰāĻā§āϤāϏā§āĻŦāϞā§āĻĒāϤāĻž, āϏāĻāĻā§āϰāĻŽāĻŖ, āĻĒā§āώā§āĻāĻŋāϰ āĻāĻžāĻāϤāĻŋ, āĻšāϰāĻŽā§āύāĻāύāĻŋāϤ āϰā§āĻ, āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏāϏāĻš āĻŦāĻŋāĻāĻŋāύā§āύ āĻāĻžāϰāĻŖā§ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical interpretation: Weakness is nonspecific and does not identify the underlying disease.
āĻŦāĻžāĻāϞāĻž: āĻļā§āϧ⧠āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻĻā§āĻā§ āϰā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āĻŦāϞāĻž āϝāĻžā§ āύāĻžāĨ¤
Patient-specific confidence: 0.99 for the complaint; below 0.40 for any specific cause.
2.2 Genital Ulcer â āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž
Definition: Loss of continuity of genital skin or mucosal epithelium producing an open lesion.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āϤā§āĻŦāĻ āĻŦāĻž āĻļā§āϞā§āώā§āĻŽāĻžāĻāĻŋāϞā§āϞāĻŋāϰ āĻāĻĒāϰāĻŋāĻāĻžāĻ āύāώā§āĻ āĻšā§ā§ āĻā§āϞāĻž āĻā§āώāϤ āϤā§āϰāĻŋ āĻšāĻā§āĻžāĨ¤
Possible causes: Syphilis, genital herpes, other sexually transmitted infections, trauma, fixed drug eruption, inflammatory disorders and malignancy.
āĻŦāĻžāĻāϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ, āĻ āύā§āϝāĻžāύā§āϝ āϏāĻāĻā§āϰāĻŽāĻŖ, āĻāĻāĻžāϤ, āĻāώā§āϧā§āϰ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž, āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āĻā§āϝāĻžāύāϏāĻžāϰāĻāύāĻŋāϤ āĻāĻžāϰāĻŖā§ āĻāĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical significance: Anogenital ulcers require structured evaluation because clinical appearance alone can be unreliable.
āĻŦāĻžāĻāϞāĻž: āĻāĻž āĻĻā§āĻāϤ⧠āĻā§āĻŽāύ, āĻŦā§āϝāĻĨāĻž āĻāĻā§ āĻāĻŋ āύāĻž āĻāĻŦāĻ āĻā§āύ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻā§âāĻāϏāĻŦ āĻāĻžā§āĻž āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻāϰāĻž āĻāĻ āĻŋāύāĨ¤
Confidence: 0.99 for need for evaluation.
2.3 Skin Rash â āϤā§āĻŦāĻā§āϰ āϰâā§āϝāĻžāĻļ
Definition: A visible alteration in skin colour, texture or surface morphology.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§ āϞāĻžāϞāĻā§ āĻĻāĻžāĻ, āĻĢā§āϏāĻā§ā§āĻŋ, āĻāĻžāĻāĻž āĻŦāĻž āĻ āύā§āϝ āϧāϰāύā§āϰ āĻĻā§āĻļā§āϝāĻŽāĻžāύ āĻĒāϰāĻŋāĻŦāϰā§āϤāύāĨ¤
Possible causes: Infection, allergy, drug reactions and inflammatory skin disease.
āĻŦāĻžāĻāϞāĻž: āϏāĻāĻā§āϰāĻŽāĻŖ, āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ, āĻāώā§āϧā§āϰ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻ āĻĨāĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻāϰā§āĻŽāϰā§āĻāĨ¤
Clinical significance: Generalized rash with genital ulceration raises concern for secondary syphilis, but the rash and ulcer may also have unrelated causes.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§ āĻāĻž āĻ āĻļāϰā§āϰ⧠āϰâā§āϝāĻžāĻļ āĻāĻāϏāĻā§āĻā§ āĻĨāĻžāĻāϞ⧠āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤ āϤāĻŦā§ āĻĻā§āĻāĻŋ āĻāĻĒāϏāϰā§āĻ āĻāĻāĻ āϰā§āĻā§āϰ āĻāĻžāϰāĻŖā§ āĻšā§ā§āĻā§âāĻāĻāĻŋ āĻāĻāύ⧠āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āύā§āĨ¤
Confidence: 0.95 for clinical relevance; 0.70 for syphilis being a leading differential.
đ§ SECTION 3. ORIGINAL CLINICAL OBSERVATION â O/E
O/E means On Examination â āϰā§āĻā§ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āĻĒāĻžāĻā§āĻž āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖāĨ¤
| Parameter | Original Record | Clinical Meaning | āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž | Confidence |
|---|---|---|---|---|
| O/E | NAD | No abnormality detected | āϏāĻžāϧāĻžāϰāĻŖ āĻĒāϰā§āĻā§āώāĻžā§ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāϤāĻž āĻāϞā§āϞā§āĻ āύā§āĻ | 0.99 |
| Blood Pressure | Approximately 130/80 mmHg | Blood pressure | āϰāĻā§āϤāĻāĻžāĻĒ āĻāύā§āĻŽāĻžāύāĻŋāĻ ā§§ā§Šā§Ļ/ā§Žā§Ļ | 0.85 |
| Pulse | Not written | Pulse not recorded | āύāĻžā§āĻŋāϰ āĻāϤāĻŋ āϞā§āĻāĻž āύā§āĻ | 0.99 |
| Temperature | Unclear symbol | No reliable numeric value | āϤāĻžāĻĒāĻŽāĻžāϤā§āϰāĻžāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŽāĻžāύ āĻŦā§āĻāĻž āϝāĻžāĻā§āĻā§ āύāĻž | 0.95 |
| Heart | Appears to indicate S1/S2; full notation unclear | Basic cardiac auscultation | āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āĻļāĻŦā§āĻĻ āĻĒāϰā§āĻā§āώāĻž | 0.70 |
| Lung | Appears clinically unremarkable | Lung examination | āĻĢā§āϏāĻĢā§āϏā§āϰ āĻĒāϰā§āĻā§āώāĻžā§ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāϤāĻž āϞā§āĻāĻž āύā§āĻ āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§ | 0.75 |
| Genital lesion | Not described | Specific examination absent | āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻžā§ā§āϰ āĻŦāĻŋāĻŦāϰāĻŖ āύā§āĻ | 0.99 |
| Skin rash | Not characterized | Rash morphology absent | āϰâā§āϝāĻžāĻļā§āϰ āĻĒā§āϰāĻā§āϤāĻŋ āϞā§āĻāĻž āύā§āĻ | 0.99 |
Clinical Observation Analysis
Finding 1: O/E: NAD does not rule out genital ulcer disease.
āĻŦāĻžāĻāϞāĻž: NAD āϞā§āĻāĻž āĻĨāĻžāĻāϞā§āĻ āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āύā§āĻ āĻāĻŋāĻāĻŦāĻž STI āύā§āĻâāĻāĻŽāύ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āĻĻā§āĻā§āĻž āϝāĻžā§ āύāĻžāĨ¤
Finding 2: Genital lesion morphology has not been documented.
āĻŦāĻžāĻāϞāĻž: āĻāĻž āĻŦā§āϝāĻĨāĻžāϝā§āĻā§āϤ āĻāĻŋ āύāĻž, āĻāĻāĻāĻŋ āύāĻž āĻāĻāĻžāϧāĻŋāĻ, āĻā§āĻĨāĻžā§, āĻāϤ āĻŦā§ āĻāĻŦāĻ āĻā§ āϧāϰāύā§āϰâāĻāĻā§āϞā§āϰ āĻā§āύ⧠āϤāĻĨā§āϝ āύā§āĻāĨ¤
Finding 3: The rash distribution is unknown.
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāϤā§āϰ āϤāĻžāϞā§, āĻĒāĻžā§ā§āϰ āϤāϞāĻž, āĻŦā§āĻ, āĻĒāĻŋāĻ āĻ āĻĨāĻŦāĻž āĻ āύā§āϝ āĻā§āĻĨāĻžā§ āϰâā§āϝāĻžāĻļ āĻšā§ā§āĻā§ āϤāĻž āϞā§āĻāĻž āύā§āĻāĨ¤
Clinical significance: These omissions substantially limit diagnostic accuracy.
Confidence: 0.99.
đ§ SECTION 4. COMPLETE HISTORY ASSESSMENT
Documented and Missing Clinical Histories
| Parameter | English Meaning | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Prescription Status |
|---|---|---|---|
| I/H | Illness/Infection History, depending on local notation | āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻ āϏā§āϏā§āĻĨāϤāĻž āĻŦāĻž āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| O/H | Occupational or Other History | āĻĒā§āĻļāĻžāĻāϤ āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| D/H | Drug History | āĻāώā§āϧ āĻā§āϰāĻšāĻŖā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| M/H | Medical History | āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| P/H | Past History | āĻ āϤā§āϤ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| F/H | Family History | āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| S/H | Sexual/Social History | āϝā§āύ āĻ āϏāĻžāĻŽāĻžāĻāĻŋāĻ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| O/S/E | Other Systemic Examination | āĻļāϰā§āϰā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āĻ āĻā§āĻā§āϰ āĻĒāϰā§āĻā§āώāĻž | Not separately documented |
| O/G/E | Meaning not defined in the original prescription | āϏāĻāĻā§āώāĻŋāĻĒā§āϤ āϰā§āĻĒāĻāĻŋāϰ āĻ āϰā§āĻĨ āĻāĻāĻžāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āύ⧠| Not documented |
| Allergy History | Drug or other allergy history | āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| Surgical History | Previous surgical history | āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻ āĻĒāĻžāϰā§āĻļāύā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| Immunization History | Vaccination history | āĻāĻŋāĻāĻž āύā§āĻā§āĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
Documentation confidence: 0.99.
History Required for Clinical Diagnosis
1. Duration of genital ulcer â āϝā§āύāĻžāĻā§āĻā§ āĻāĻž āĻāϤāĻĻāĻŋāύ āϧāϰā§?
Ulcer onset and progression help distinguish acute from chronic disease.
āĻāĻž āĻāĻāύ āĻšā§ā§āĻā§ āĻāĻŦāĻ āĻĻāĻŋāύ āĻĻāĻŋāύ āĻŦāĻžā§āĻā§ āύāĻžāĻāĻŋ āĻāĻŽāĻā§âāĻāĻāĻŋ āĻāĻžāύāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
2. Pain and tenderness â āĻāĻžā§ā§ āĻŦā§āϝāĻĨāĻž āĻāĻā§ āĻāĻŋ?
Syphilitic chancres are often painless; HSV lesions are often painful. However, these are tendencies rather than definitive diagnostic rules.
āϏāĻŋāĻĢāĻŋāϞāĻŋāϏā§āϰ āĻāĻž āĻ āύā§āĻ āϏāĻŽā§ āĻŦā§āϝāĻĨāĻžāĻšā§āύ āĻāĻŦāĻ āĻšāĻžāϰāĻĒāĻŋāϏā§āϰ āĻāĻž āĻ āύā§āĻ āϏāĻŽā§ āĻŦā§āϝāĻĨāĻžāϝā§āĻā§āϤ āĻšā§āĨ¤ āĻāĻŋāύā§āϤ⧠āĻļā§āϧ⧠āĻŦā§āϝāĻĨāĻž āĻĻāĻŋā§ā§ āύāĻŋāĻļā§āĻāĻŋāϤ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻā§āĻž āϝāĻžā§ āύāĻžāĨ¤
3. Vesicles â āĻĢā§āϏāĻāĻž āĻšā§ā§āĻāĻŋāϞ āĻāĻŋ?
Grouped vesicles preceding ulceration support HSV infection.
āĻāĻž āĻšāĻā§āĻžāϰ āĻāĻā§ āĻĒāĻžāύāĻŋāĻāϰāĻž āĻĢā§āϏāĻāĻž āĻĨāĻžāĻāϞ⧠āĻšāĻžāϰāĻĒāĻŋāϏā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŦāĻžā§ā§āĨ¤
4. Previous sexual exposure â āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āϝā§āύ-āϏāĻāϏā§āĻĒāϰā§āĻļā§āϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
A confidential, nonjudgmental assessment is relevant for STI risk evaluation.
āĻā§āĻĒāύā§ā§āϤāĻž āĻŦāĻāĻžā§ āϰā§āĻā§ āĻĒā§āϰā§ā§āĻāύā§ā§ āϝā§āύāϏā§āĻŦāĻžāϏā§āĻĨā§āϝā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
5. Previous STI treatment â āĻāĻā§ āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻšā§ā§āĻā§ āĻāĻŋ?
Past syphilis treatment affects interpretation of treponemal serology.
āĻāĻā§ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻšā§ā§ āĻĨāĻžāĻāϞ⧠āϰāĻā§āϤāĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻŦā§āϝāĻžāĻā§āϝāĻžā§ āϤāĻžāϰ āĻĒā§āϰāĻāĻžāĻŦ āĻĒā§ā§āĨ¤
6. Rash distribution â āϰâā§āϝāĻžāĻļ āĻā§āĻĨāĻžā§ āĻā§āĻĨāĻžā§?
Palms, soles, mucous membranes and generalized distribution are clinically relevant.
āĻšāĻžāϤā§āϰ āϤāĻžāϞā§, āĻĒāĻžā§ā§āϰ āϤāϞāĻž āĻŦāĻž āĻŽā§āĻā§ āĻĻāĻžāĻ āĻĨāĻžāĻāϞ⧠āĻā§āϰā§āϤā§āĻŦ āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
7. Diabetes and HIV status â āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏ āĻ HIV-āĻāϰ āĻ āĻŦāϏā§āĻĨāĻžāĨ¤
These may affect infection severity and healing.
āĻāĻŋāĻā§ āϰā§āĻā§ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦā§āĻļāĻŋ āĻāĻāĻŋāϞ āĻšāϤ⧠āĻĒāĻžāϰ⧠āĻāĻŦāĻ āĻāĻž āĻļā§āĻāĻžāϤ⧠āϏāĻŽā§ āϞāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.98 for relevance of history collection.
Important: āĻāĻā§āϞ⧠āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒā§āϰāĻļā§āύ; āϰā§āĻā§āϰ āĻāĻžāĻ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻāϤā§āϤāϰ āύā§āĨ¤
đ§ SECTION 5. INVESTIGATIONS AND CLINICAL INTERPRETATION
5.1 Investigations Ordered by the Doctor
Investigation 1 â CBC
Full Form: Complete Blood Count.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻĒā§āϰā§āĻŖ āϰāĻā§āϤāĻāĻŖāĻŋāĻāĻž āĻāĻŖāύāĻžāĨ¤
Clinical purpose: Assessment of haemoglobin, white blood cells and platelet count.
āĻŦāĻžāĻāϞāĻž: āϰāĻā§āϤāϏā§āĻŦāϞā§āĻĒāϤāĻž, āϰāĻā§āϤā§āϰ āĻŦāĻŋāĻāĻŋāύā§āύ āĻā§āώā§āϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāĻŦāĻ āĻĒā§āϞā§āĻāϞā§āĻā§āϰ āĻ āĻŦāϏā§āĻĨāĻž āύāĻŋāϰā§āĻŖā§āĨ¤
Patient-specific importance: Weakness is present, and prolonged linezolid exposure can affect blood-cell production.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāĻŦāĻ Linezolid-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰāĻā§āϤāϏāĻāĻā§āϰāĻžāύā§āϤ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖā§ CBC āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Doctor ordered: Yes.
Result available: No.
Confidence: 0.99.
Investigation 2 â VDRL
Full Form: Venereal Disease Research Laboratory test.
āĻŦāĻžāĻāϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŽā§āϞā§āϝāĻžā§āύ⧠āĻŦā§āϝāĻŦāĻšā§āϤ āύāύ-āĻā§āϰā§āĻĒā§āύā§āĻŽāĻžāϞ āϰāĻā§āϤāĻĒāϰā§āĻā§āώāĻžāĨ¤
Clinical purpose: Screening/assessment of syphilis and quantitative monitoring when reported with titres.
āĻŦāĻžāĻāϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āύāĻŋāϰā§āĻŖā§ā§ āϏāĻšāĻžā§āϤāĻž āĻāĻŦāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĒāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ titre āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖāĨ¤
Patient-specific importance: Genital ulcer and rash together make syphilis an important differential.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āĻ āϰâā§āϝāĻžāĻļā§āϰ āĻāĻžāϰāĻŖā§ VDRL āĻĒāϰā§āĻā§āώāĻž āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤāĨ¤
Doctor ordered: Yes.
Result available: No.
Confidence: 0.99.
Important Limitation
A VDRL result alone cannot reliably establish or exclude syphilis.
āĻŦāĻžāĻāϞāĻž: VDRL positive āĻšāϞā§āĻ āϏāĻā§āϰāĻŋā§ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšā§ āύāĻž āĻāĻŦāĻ negative āĻšāϞā§āĻ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻĒāϰā§āϝāĻžā§ā§āϰ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻĒā§āϰā§āĻĒā§āϰāĻŋ āĻŦāĻžāĻĻ āϝāĻžā§ āύāĻžāĨ¤
Nontreponemal testing should be interpreted alongside a treponemal assay and relevant clinical history.
āĻŦāĻžāĻāϞāĻž: VDRL/RPR-āĻāϰ āϏāĻā§āĻā§ TPPA āĻ āĻĨāĻŦāĻž āĻ āύā§āϝ āĻāĻĒāϝā§āĻā§āϤ treponemal test āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Evidence: CDC Laboratory Recommendations for Syphilis Testing, 2024.
5.2 Additional Investigations Recommended
| Test | English Purpose | āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž | Priority |
|---|---|---|---|
| Quantitative RPR/VDRL | Baseline syphilis titre | āϏāĻŋāĻĢāĻŋāϞāĻŋāϏā§āϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ titre āύāĻŋāϰā§āϧāĻžāϰāĻŖ | High |
| TPPA or treponemal EIA | Treponemal confirmation | āϏāĻŋāĻĢāĻŋāϞāĻŋāϏā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻĄāĻŋ āĻĒāϰā§āĻā§āώāĻž | High |
| HSV-1/HSV-2 PCR from lesion | Detect herpesvirus DNA | āĻāĻž āĻĨā§āĻā§ āĻšāĻžāϰāĻĒāĻŋāϏ āĻāĻžāĻāϰāĻžāϏ āĻļāύāĻžāĻā§āϤ | High if lesion available |
| HIV Ag/Ab | Screen for HIV infection | HIV āϏāĻāĻā§āϰāĻŽāĻŖ āĻĒāϰā§āĻā§āώāĻž | High |
| CBC with platelets | Anaemia and linezolid monitoring | āϰāĻā§āϤāϏā§āĻŦāϞā§āĻĒāϤāĻž āĻ Linezolid āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āϝāĻžāĻāĻžāĻ | High |
| Fasting glucose/HbA1c | Assess diabetes | āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏ āĻŽā§āϞā§āϝāĻžā§āύ | Conditional |
| Bacterial culture | Identify bacterial pathogen | āĻĒā§āĻāĻ āĻŦāĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϏāĻāĻā§āϰāĻŽāĻŖ āĻĨāĻžāĻāϞ⧠āĻā§āĻŦāĻžāĻŖā§ āĻļāύāĻžāĻā§āϤ | Conditional |
| Renal function | Assess kidney function | āĻāĻŋāĻĄāύāĻŋāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āύāĻŋāϰā§āĻŖā§ | Conditional |
| Lesion biopsy | Evaluate atypical/nonhealing lesions | āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŦāĻž āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻāĻž āĻĒāϰā§āĻā§āώāĻž | Conditional |
Confidence: 0.95â0.99 depending on clinical indication.
đ§ SECTION 6. DEFINITION, ETIOLOGY AND PATHOPHYSIOLOGY
6.1 Genital Ulcer Disease â āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž
Definition: A clinical syndrome involving ulcerative lesions of the genital or adjacent anogenital region.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻ āĻ āĻĨāĻŦāĻž āϤāĻžāϰ āĻāĻļāĻĒāĻžāĻļā§ āĻā§āώāϤ āĻŦāĻž āĻāϞāϏāĻžāϰ āϏā§āώā§āĻāĻŋāϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻĒā§āϰāĻāĻžāĻļ āĻĒāĻžāĻā§āĻž āĻāĻāĻāĻŋ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŽāϏā§āϝāĻžāĨ¤
Etiology: Infectious and noninfectious causes.
āĻŦāĻžāĻāϞāĻž: āϏāĻāĻā§āϰāĻŽāĻŖāĻāύāĻŋāϤ āĻāĻŦāĻ āϏāĻāĻā§āϰāĻŽāĻŖāĻŦāĻŋāĻšā§āύ āĻāĻā§ āĻāĻžāϰāĻŖ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Pathophysiology: Damage to epidermal or mucosal integrity results in ulcer formation through infection, inflammation, trauma or other tissue-destructive processes.
āĻŦāĻžāĻāϞāĻž: āϏāĻāĻā§āϰāĻŽāĻŖ, āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āĻāĻāĻžāϤ⧠āϤā§āĻŦāĻ āĻ āĻļā§āϞā§āώā§āĻŽāĻžāĻāĻŋāϞā§āϞāĻŋāϰ āĻā§āώ āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻšāϞ⧠āĻāĻž āϤā§āϰāĻŋ āĻšā§āĨ¤
Clinical features: Painful or painless ulcer, erythema, discharge, vesicles or lymphadenopathy depending on cause.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻĨāĻžāϝā§āĻā§āϤ āĻŦāĻž āĻŦā§āϝāĻĨāĻžāĻšā§āύ āĻāĻž, āϞāĻžāϞāĻāĻžāĻŦ, āĻĒā§āĻāĻ, āĻĢā§āϏāĻāĻž āĻ āĻĨāĻŦāĻž āĻā§āĻāĻāĻāĻŋāϰ āϞāĻŋāĻŽā§āĻĢ āύā§āĻĄ āĻĢā§āϞ⧠āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.99 for general medical description.
6.2 Syphilis â āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ
Definition: A bacterial sexually transmitted infection caused by Treponema pallidum.
āĻŦāĻžāĻāϞāĻž: āĻā§āϰā§āĻĒā§āύā§āĻŽāĻž āĻĒā§āϝāĻžāϞāĻŋāĻĄāĻžāĻŽ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻāĻžāϰāĻŖā§ āϏā§āώā§āĻ āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Etiology: Infection with T. pallidum.
Pathophysiology: Organism dissemination and host inflammatory responses produce staged systemic manifestations.
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŦāĻžāĻŖā§ āĻļāϰā§āϰ⧠āĻā§āĻŋā§ā§ āĻŦāĻŋāĻāĻŋāύā§āύ āĻ āĻā§āĻā§ āĻĒā§āϰāĻĻāĻžāĻš āϏā§āώā§āĻāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical features: Primary chancre, lymphadenopathy, secondary rash, mucosal lesions and other stage-dependent findings.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻĒāϰā§āϝāĻžā§ā§ āĻāĻž āĻāĻŦāĻ āĻĒāϰāĻŦāϰā§āϤ⧠āĻĒāϰā§āϝāĻžā§ā§ āϰâā§āϝāĻžāĻļāϏāĻš āύāĻžāύāĻž āĻāĻĒāϏāϰā§āĻ āĻĻā§āĻāĻž āĻĻāĻŋāϤ⧠āĻĒāĻžāϰā§āĨ¤
Important distinction: Primary and secondary manifestations can overlap; the presence of both complaints does not confirm either stage.
āĻŦāĻžāĻāϞāĻž: āĻāĻž āĻ āϰâā§āϝāĻžāĻļ āĻāĻāϏāĻā§āĻā§ āĻĨāĻžāĻāϞā§āĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻāĻā§ āϰā§āĻā§āϰ āĻĒāϰā§āϝāĻžā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Patient-specific diagnostic relevance: High.
Confidence: 0.70 for this differential.
6.3 Genital Herpes â āϝā§āύāĻžāĻā§āĻā§āϰ āĻšāĻžāϰāĻĒāĻŋāϏ
Definition: Genital infection caused by herpes simplex virus, usually HSV-1 or HSV-2.
āĻŦāĻžāĻāϞāĻž: HSV-1 āĻ āĻĨāĻŦāĻž HSV-2 āĻāĻžāĻāϰāĻžāϏā§āϰ āĻāĻžāϰāĻŖā§ āϝā§āύāĻžāĻā§āĻā§ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Pathophysiology: Viral replication in epithelial cells produces vesicles and ulceration; latency can develop in sensory ganglia.
āĻŦāĻžāĻāϞāĻž: āĻāĻžāĻāϰāĻžāϏ āϤā§āĻŦāĻā§āϰ āĻā§āώ⧠āĻŦāĻāĻļāĻŦā§āĻĻā§āϧāĻŋ āĻāϰ⧠āĻĢā§āϏāĻāĻž āĻ āĻāĻž āϤā§āϰāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰ⧠āĻāĻŦāĻ āϏā§āύāĻžā§ā§āϤ⧠āϏā§āĻĒā§āϤ āĻ āĻŦāϏā§āĻĨāĻžā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical features: Pain, vesicles, ulcers, burning, dysuria and recurrence.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻĨāĻž, āĻĢā§āϏāĻāĻž, āĻāĻž, āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž, āĻĒā§āϰāϏā§āϰāĻžāĻŦā§ āĻ āϏā§āĻŦāϏā§āϤāĻŋ āĻŦāĻž āĻŦāĻžāϰāĻŦāĻžāϰ āĻāĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Patient-specific limitation: Vesicles, ulcer pain and recurrence are not documented.
Confidence: 0.65 as a possible cause.
6.4 Secondary Bacterial Infection â āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ
Definition: Bacterial infection occurring within damaged or diseased skin.
āĻŦāĻžāĻāϞāĻž: āĻāĻā§ āĻĨā§āĻā§ āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āϤā§āĻŦāĻ āĻŦāĻž āĻāĻžā§ā§āϰ āĻāĻĒāϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Possible organisms: Staphylococcus aureus and Streptococcus pyogenes in relevant superficial skin infections.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻā§ āϤā§āĻŦāĻā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖā§ āϏā§āĻā§āϝāĻžāĻĢāĻžāĻāϞā§āĻāĻā§āĻāĻžāϏ āĻ āϏā§āĻā§āϰā§āĻĒāĻā§āĻāĻā§āĻāĻžāϏ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āĻā§āĻŋāϤ āĻĨāĻžāĻā§āĨ¤
Clinical features: Purulence, surrounding erythema, warmth, crusting or spreading inflammation.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āĻāĻ, āϞāĻžāϞāĻāĻžāĻŦ, āĻāϰāĻŽ āĻ āύā§āĻā§āϤāĻŋ, āĻā§āϏāĻž āĻŦāĻž āϏāĻāĻā§āϰāĻŽāĻŖ āĻā§āĻŋā§ā§ āĻĒā§āĻžāĨ¤
Patient-specific interpretation: Mupirocin and linezolid suggest possible concern for bacterial infection, but this does not prove bacterial involvement.
āĻŦāĻžāĻāϞāĻž: āĻāώā§āϧ āĻĻā§āĻā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāύā§āĻĻā§āĻš āĻŦā§āĻāĻž āĻā§āϞā§āĻ āϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
Confidence: 0.50 for this patient.
đ§ SECTION 7. DIFFERENTIAL DIAGNOSIS
| Rank | Differential Diagnosis | Supporting Evidence | Missing Evidence | Assessment Confidence |
|---|---|---|---|---|
| 1 | Syphilis â āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ | Genital ulcer + rash + VDRL ordered | Serology, lesion morphology, exposure history | 0.70 |
| 2 | Genital HSV Infection â āĻā§āύāĻŋāĻāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ | Genital ulcer | Pain, vesicles, recurrence, PCR | 0.65 |
| 3 | Secondary Bacterial Infection â āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ | Antibiotic prescription | No documented pus, cellulitis or culture | 0.50 |
| 4 | Fixed Drug Eruption â āĻāώā§āϧāĻāύāĻŋāϤ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϏā§āĻĨāĻžāύā§āϰ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž | Genital erosion and rash can coexist | Drug exposure history absent | 0.40 |
| 5 | Candidal/Erosive Balanitis â āĻĢāĻžāĻā§āĻāĻžāϞ āĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻŦā§āϝāĻžāϞāĻžāύāĻžāĻāĻāĻŋāϏ | Genital skin lesion possible | Local morphology unknown | 0.35 |
| 6 | Chancroid â āĻļā§āϝāĻžāĻāĻā§āϰā§ā§āĻĄ | Genital ulcer possible | Typical painful ulcer/tender nodes not documented | 0.30 |
| 7 | Genital Malignancy â āϝā§āύāĻžāĻā§āĻā§āϰ āĻā§āϝāĻžāύāϏāĻžāϰ | Consider in persistent atypical ulcer | No suspicious morphology or duration documented | 0.30 |
| 8 | Behçet Disease â āĻŦā§āĻšāϏā§āĻ āϰā§āĻ | Genital ulcer possible | Recurrent oral ulcers and other findings absent | 0.20 |
Interpretation: These scores express confidence in considering a diagnosis, not the patient’s statistical probability of having it.
āĻŦāĻžāĻāϞāĻž: āĻāĻā§āϞ⧠āϰā§āĻ āĻšāĻā§āĻžāϰ āĻļāϤāĻžāĻāĻļ āύā§; āĻā§āύ āϰā§āĻāĻāĻŋ āĻāϤāĻāĻž āĻā§āϰā§āϤā§āĻŦ āĻĻāĻŋā§ā§ āĻĒāϰā§āĻā§āώāĻž āĻāϰāĻž āĻāĻāĻŋāϤ āϤāĻžāϰ āĻāĻāĻāĻŋ āϤāĻĨā§āϝāĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
đŠ SECTION 8. FINAL WORKING CLINICAL DIAGNOSIS
FINAL PROVISIONAL / WORKING Dx
Undifferentiated Genital Ulcer Disease (GUD) with Associated Cutaneous Rash and Generalized Weakness â Rule Out Syphilis and Genital Herpes Simplex Virus Infection; Consider Secondary Superficial Bacterial Infection.
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§
āϝā§āύāĻžāĻā§āĻā§ āĻāĻžāϰāĻŖ āĻ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻāĻž, āϏāĻā§āĻā§ āϤā§āĻŦāĻā§ āϰâā§āϝāĻžāĻļ āĻ āϏāĻžāϰā§āĻŦāĻŋāĻ āĻĻā§āϰā§āĻŦāϞāϤāĻžāĨ¤ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻāĻŦāĻ āĻā§āύāĻŋāĻāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤ āĻā§āώāϤ⧠āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ āĻĨāĻžāĻāĻžāĻ āϏāĻŽā§āĻāĻŦāĨ¤
Confidence in symptom-based working diagnosis: 0.99.
Confidence in syphilis as a differential: 0.70.
Confidence in genital herpes as a differential: 0.65.
Confidence in secondary bacterial infection: 0.50.
Definitive etiological diagnosis: Not established.
Prescription-Ready Short Dx
Dx: Genital Ulcer Disease (Etiology Undetermined) with Skin Rash â R/O Syphilis / Genital HSV; ?Secondary Bacterial Infection.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āĻ āϤā§āĻŦāĻā§āϰ āϰâā§āϝāĻžāĻļ; āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ āĻšāĻžāϰāĻĒāĻŋāϏ āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§āĨ¤
đ§ SECTION 9. ORIGINAL PRESCRIPTION DRUG SUMMARY
Table 1 â Original Drugs and Clinical Purpose
| No. | Original Brand | Generic | MedEx Therapeutic Class | Possible Clinical Purpose |
|---|---|---|---|---|
| 1 | Linzolid 600 mg | Linezolid | Macrolides â MedEx label, pharmacologically incorrect | Suspected bacterial infection |
| 2 | Fenadin 120 mg | Fexofenadine | Anti-histamine | Allergy/rash-associated itching |
| 3 | DDR 30 mg | Dexlansoprazole | Proton Pump Inhibitor | Acid suppression |
| 4 | Coralcin-D | Coral calcium + Vitamin D3 | Specific mineral & vitamin combined preparations | Calcium/vitamin supplementation |
| 5 | Muron 2% | Mupirocin | Topical Antibiotic preparations | Superficial bacterial skin infection |
| 6 | Supravit | Multivitamin [Adult preparation] | Specific combined vitamin preparations | Vitamin supplementation |
Confidence: 0.98 for brand identification and verified generic information.
Original Dosing Transcription
The prescription appears to contain the following instructions:
- Linzolid 600 mg: Approximately 1+0+1; duration appears 20 days.
- Fenadin 120 mg: Appears once daily; duration handwriting is unclear.
- DDR 30 mg: Appears once daily with a fasting instruction; exact duration unclear.
- Coralcin-D: Appears once daily; duration uncertain.
- Muron 2%: Topical application; frequency and duration require confirmation, although the duration appears close to 20 days.
- Supravit: Appears once daily; duration uncertain.
Clinical safety note: These are transcriptions of a handwritten prescription, not independently validated dosing instructions. Illegible directions must be confirmed with the original prescriber or dispensing pharmacist.
Transcription confidence: 0.55â0.85 depending on the instruction.
đ§ SECTION 10. COMPLETE 17-PARAMETER MEDICINE REVIEW
đŠ MEDICINE 1 â LINZOLID 600 MG
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Linezolid â āϞāĻžāĻāύāĻā§āϞāĻŋāĻĄāĨ¤
An antibacterial agent used against selected Gram-positive organisms.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻā§āϰāĻžāĻŽ-āĻĒāĻāĻŋāĻāĻŋāĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻŦāĻŋāϰā§āĻĻā§āϧ⧠āĻāĻžāϰā§āϝāĻāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Linzolid 600 mg Tablet â Incepta Pharmaceuticals Ltd.
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Arlin, Linez, Linexil, Lizolix, Lizox, Linbid and other linezolid brands.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ āĻŦāĻŋāĻāĻŋāύā§āύ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤ strength āĻ formulation āĻ āĻŦāĻļā§āϝāĻ āĻŽāĻŋāϞāĻŋā§ā§ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
4. MedEx Therapeutic Class â āĻŽā§āĻĄāĻāĻā§āϏ āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻļā§āϰā§āĻŖāĻŋ
MedEx displays: Macrolides.
Important correction: This classification is inconsistent with established pharmacology.
āĻŦāĻžāĻāϞāĻž: MedEx-āĻ Macrolides āϞā§āĻāĻž āĻĨāĻžāĻāϞā§āĻ Linezolid āĻāϏāϞ⧠Macrolide āύā§āĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Oxazolidinone antibiotic â āĻ āĻā§āϏāĻžāĻā§āϞāĻŋāĻĄāĻŋāύā§āύ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻāĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Treatment of selected Gram-positive bacterial infections, including certain resistant organisms.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ, āĻŦāĻŋāĻļā§āώāϤ āĻāĻŋāĻā§ āĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
7. Why Doctor Prescribed It â āĻāĻ āϰā§āĻā§āĻā§ āĻā§āύ āĻĻāĻŋā§ā§āĻā§āύ?
The physician may have suspected bacterial infection involving the genital lesion or skin.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻ āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āĻ āĻĨāĻŦāĻž āϤā§āĻŦāĻā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ āϏāύā§āĻĻā§āĻš āĻāϰ⧠āĻĻāĻŋā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
However: No definitive bacterial diagnosis is documented.
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Diarrhoea, nausea, headache, thrombocytopenia, anaemia, myelosuppression, peripheral neuropathy, optic neuropathy and serotonin syndrome.
āĻŦāĻžāĻāϞāĻž: āĻĄāĻžā§āϰāĻŋā§āĻž, āĻŦāĻŽāĻŋāĻāĻžāĻŦ, āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āĻĒā§āϞā§āĻāϞā§āĻ āĻāĻŽā§ āϝāĻžāĻā§āĻž, āϰāĻā§āϤāϏā§āĻŦāϞā§āĻĒāϤāĻž, āĻ āϏā§āĻĨāĻŋāĻŽāĻā§āĻāĻžāϰ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻāĻŽā§ āϝāĻžāĻā§āĻž, āϏā§āύāĻžā§ā§āϰ āĻā§āώāϤāĻŋ āĻāĻŦāĻ āĻāĻŋāĻā§ āĻāώā§āϧā§āϰ āϏāĻā§āĻā§ āĻŦāĻŋāĻĒāĻā§āĻāύāĻ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ MedEx āϞāĻŋāĻāĻ
Linzolid 600 mg â MedEx Bangladesh
10. Unit Price, Strip Price and Other Forms â āĻĻāĻžāĻŽ āĻ āϧāϰāύ
Unit price: ā§ŗ85.00
Strip price: ā§ŗ850.00 per 10-tablet strip.
Other forms: 400 mg tablet, 100 mg/5 mL oral suspension and 2 mg/mL IV infusion.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāϤāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ ā§Žā§Ģ āĻāĻžāĻāĻž āĻāĻŦāĻ ā§§ā§ĻāĻāĻŋāϰ āϏā§āĻā§āϰāĻŋāĻĒ ā§Žā§Ģā§Ļ āĻāĻžāĻāĻžāĨ¤
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and preventing formation of the initiation complex.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻĒā§āϰā§āĻāĻŋāύ āϤā§āϰāĻŋāϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āϧāĻžāĻĒ āĻŦāύā§āϧ āĻāϰ⧠āĻā§āĻŦāĻžāĻŖā§āϰ āĻŦā§āĻĻā§āϧāĻŋ āĻĒā§āϰāϤāĻŋāϰā§āϧ āĻāϰā§āĨ¤
12. Drug Indications â āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§?
Selected pneumonia, complicated skin and soft-tissue infections, resistant Gram-positive infections and VRE infection.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āύāĻŋāĻāĻŽā§āύāĻŋā§āĻž, āĻāĻāĻŋāϞ āϤā§āĻŦāĻā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻŦāĻ āĻāĻŋāĻā§ āĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§āĨ¤
13. Drug Interactions + Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
Important interactions include MAO inhibitors, serotonergic antidepressants, certain opioids and sympathomimetic medicines.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻā§ antidepressant, MAOI, opioid āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧā§āϰ āϏāĻā§āĻā§ āĻŦāĻŋāĻĒāĻā§āĻāύāĻ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Contraindications include hypersensitivity and use with MAO inhibitors within the contraindicated interval.
āĻŦāĻžāĻāϞāĻž: Linezolid-āĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻ āĻĨāĻŦāĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ MAOI āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ⧠āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž āϰā§ā§āĻā§āĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Weekly CBC monitoring is recommended during linezolid treatment, especially when therapy exceeds two weeks.
āĻŦāĻžāĻāϞāĻž: Linezolid āĻŦā§āϝāĻŦāĻšāĻžāϰāĻāĻžāϞ⧠āύāĻŋā§āĻŽāĻŋāϤ CBC āĻĒāϰā§āĻā§āώāĻž āĻāϰā§āϰāĻŋ, āĻŦāĻŋāĻļā§āώ āĻāϰ⧠āĻĻā§āĻ āϏāĻĒā§āϤāĻžāĻšā§āϰ āĻŦā§āĻļāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻžā§āĨ¤
Check for thrombocytopenia, anaemia, neuropathy, visual symptoms and serotonin syndrome.
āĻŦāĻžāĻāϞāĻž: āϰāĻā§āϤāĻāĻŖāĻŋāĻāĻž, āĻĒā§āϞā§āĻāϞā§āĻ, āϏā§āύāĻžā§ā§ āĻ āĻĻā§āώā§āĻāĻŋāĻļāĻā§āϤāĻŋāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻŽāϏā§āϝāĻž āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āϏā§āĻŦāύāĻŦāĻŋāϧāĻŋ
For selected serious infections, an adult regimen is 600 mg every 12 hours; duration depends on the indication.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻĒā§āϰāĻžāĻĒā§āϤāĻŦā§āϏā§āĻāĻĻā§āϰ ⧧⧍ āĻāĻŖā§āĻāĻž āĻ āύā§āϤāϰ ā§Ŧā§Ļā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž. āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§, āϤāĻŦā§ āϰā§āĻ āĻ āύā§āϝāĻžā§ā§ āĻŽā§ā§āĻžāĻĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āĻšā§āĨ¤
Patient-specific concern: The handwritten regimen appears to involve a prolonged course. Its appropriateness cannot be confirmed without the bacterial diagnosis.
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Use during pregnancy only when justified by individual benefitârisk assessment; linezolid enters breast milk.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§ā§āĻāύ āĻ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻāĻžāϰ āĻāϰ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϤ⧠āĻšā§āĨ¤ āϏā§āϤāύā§āϝāĻĻā§āĻā§āϧ⧠āĻāώā§āϧ āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Patient relevance: The patient is male; this information is included for pharmacological completeness.
17. Other Combinations â āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
MedEx lists alternative strengths and dosage forms. A relevant fixed-dose linezolid combination is not established on the reviewed brand page.
āĻŦāĻžāĻāϞāĻž: ā§Ēā§Ļā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž. āĻā§āϝāĻžāĻŦāϞā§āĻāϏāĻš āĻ āύā§āϝāĻžāύā§āϝ strength āĻ formulation āĻĒāĻžāĻā§āĻž āϝāĻžā§; āĻāĻā§āϞ⧠āĻāϞāĻžāĻĻāĻž combination drug āύā§āĨ¤
đ§ Clinical Safety Verdict
Potentially inappropriate without clear bacterial indication.
Linezolid does not provide recommended definitive treatment for syphilis or genital herpes.
āĻŦāĻžāĻāϞāĻž: āĻļā§āϧ⧠āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āĻ āϰâā§āϝāĻžāĻļ āĻĨāĻžāĻāĻžāϰ āĻāĻžāϰāĻŖā§ āĻĻā§āϰā§āĻāĻĻāĻŋāύ Linezolid āĻŦā§āϝāĻŦāĻšāĻžāϰāĻā§ āϝāĻĨāĻžāϝāĻĨ āĻŦāϞāĻž āϝāĻžā§ āύāĻžāĨ¤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āϝāĻžāĻāĻžāĻ āĻāϰā§āϰāĻŋāĨ¤
Pharmacology confidence: 0.99.
Patient-specific indication confidence: 0.45.
Source:
đŠ MEDICINE 2 â FENADIN 120 MG
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Fexofenadine Hydrochloride â āĻĢā§āĻā§āϏā§āĻĢā§āύāĻžāĻĄāĻŋāύ āĻšāĻžāĻāĻĄā§āϰā§āĻā§āϞā§āϰāĻžāĻāĻĄāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Fenadin 120 mg Tablet â Renata PLC.
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Other fexofenadine brands are available in Bangladesh; equivalent products should be selected from the MedEx alternate-brand listing after verifying strength.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤ ⧧⧍ā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž. strength āĻŽāĻŋāϞāĻŋā§ā§ āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
4. MedEx Therapeutic Class â āĻŽā§āĻĄāĻāĻā§āϏ āĻļā§āϰā§āĻŖāĻŋ
Anti-histamine â āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Second-generation peripheral H1-antihistamine â āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒā§āϰāĻāύā§āĻŽā§āϰ H1 āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύāĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Relief of allergic rhinitis and urticaria-associated symptoms.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻšāĻžāĻāĻāĻŋ, āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋ āĻĒā§āĻž, āĻāĻžāĻāĻž āĻāĻ āĻž āĻ āĻā§āϞāĻāĻžāύāĻŋ āĻāĻŽāĻžāϤ⧠āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§āĨ¤
7. Why Doctor Prescribed It â āĻāĻ āϰā§āĻā§āĻā§ āĻā§āύ āĻĻāĻŋā§ā§āĻā§āύ?
Possibly for itching or allergic symptoms associated with skin rash.
āĻŦāĻžāĻāϞāĻž: āϰâā§āϝāĻžāĻļā§āϰ āϏāĻā§āĻā§ āĻā§āϞāĻāĻžāύāĻŋ āĻŦāĻž āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āĻĨāĻžāĻāϞ⧠āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝ āĻĻāĻŋā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
Limitation: Itching was not explicitly documented.
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Headache, nausea, dizziness and occasional drowsiness.
āĻŦāĻžāĻāϞāĻž: āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āĻŦāĻŽāĻŋāĻāĻžāĻŦ, āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž āĻ āĻāĻāύ⧠āĻā§āĻŽāĻā§āĻŽ āĻāĻžāĻŦāĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻāĻ
Fenadin 120 mg â MedEx Bangladesh
10. Unit Price, Strip Price and Other Forms â āĻĻāĻžāĻŽ āĻ āϧāϰāύ
Unit price: ā§ŗ9.00
Strip price: ā§ŗ90.00.
Other forms: 60 mg tablet, 180 mg tablet, 30 mg dispersible tablet and oral suspension.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāϤāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ ā§¯ āĻāĻžāĻāĻž; ā§§ā§ĻāĻāĻŋāϰ āϏā§āĻā§āϰāĻŋāĻĒ ā§¯ā§Ļ āĻāĻžāĻāĻžāĨ¤
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Blocks peripheral histamine H1-receptor activity.
āĻŦāĻžāĻāϞāĻž: āĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύā§āϰ āĻĒā§āϰāĻāĻžāĻŦ āĻāĻŽāĻŋā§ā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻ āĻā§āϞāĻāĻžāύāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āĻāĻĒāĻļāĻŽ āĻāϰā§āĨ¤
12. Drug Indications â āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§?
Allergic rhinitis and urticaria.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻ āϰāĻžāĻāύāĻžāĻāĻāĻŋāϏ āĻ āĻāϰā§āĻāĻŋāĻā§āϰāĻŋā§āĻžāĨ¤
13. Drug Interactions + Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
Aluminium/magnesium-containing antacids may reduce absorption; fruit juices can reduce bioavailability. Avoid in hypersensitivity.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻā§ āĻ ā§āϝāĻžāύā§āĻāĻžāϏāĻŋāĻĄ āĻ āĻĢāϞā§āϰ āϰāϏ āĻāώā§āϧā§āϰ āĻļā§āώāĻŖ āĻāĻŽāĻžāϤ⧠āĻĒāĻžāϰā§; āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώāĻŋāĻĻā§āϧāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Renal impairment may require a lower starting dose.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻĄāύāĻŋāϰ āϏāĻŽāϏā§āϝāĻžā§ āĻāĻŽ āĻŽāĻžāϤā§āϰāĻž āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž
Adults may receive 120 mg once daily for an appropriate indication.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻžāĻĒā§āϤāĻŦā§āϏā§āĻāĻĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āϰā§āĻā§ āĻĻā§āύāĻŋāĻ āĻāĻāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§āĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Individual benefitârisk assessment is needed.
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ⧠āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āϏāϤāϰā§āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
Other fexofenadine preparations and strengths are available; an exact fixed combination should not be assumed from the brand name.
āĻŦāĻžāĻāϞāĻž: āĻŦāĻŋāĻāĻŋāύā§āύ strength āĻ formulation āϰā§ā§āĻā§; āϏā§āĻā§āϞ⧠āĻāĻāĻ āϧāϰāύā§āϰ combination āύā§āĨ¤
đ§ Clinical Verdict
Appropriate for relevant allergic symptoms, but not a treatment for an infectious genital ulcer.
āĻŦāĻžāĻāϞāĻž: āĻā§āϞāĻāĻžāύāĻŋ āĻāĻŽāĻžāϤ⧠āĻāĻžāϰā§āϝāĻāϰ āĻšāϤ⧠āĻĒāĻžāϰā§, āĻāĻŋāύā§āϤ⧠āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ āĻāĻŋāĻāĻŦāĻž āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻžā§ā§āϰ āĻŽā§āϞ āĻāĻžāϰāĻŖ āϏāĻžāϰāĻžā§ āύāĻžāĨ¤
Drug confidence: 0.99.
Patient-specific indication confidence: 0.60.
Source:
đŠ MEDICINE 3 â DDR 30 MG
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Dexlansoprazole â āĻĄā§āĻā§āϏāϞā§āϝāĻžāύāϏā§āĻĒā§āϰāĻžāĻāϞāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
DDR 30 mg EC Capsule â ACME Laboratories Ltd.
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Aslan-D, Canalia, Delanix, Delanzo, Delpraz and other dexlansoprazole brands.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ āĻ āύā§āϝ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
4. MedEx Therapeutic Class â āĻŽā§āĻĄāĻāĻā§āϏ āĻļā§āϰā§āĻŖāĻŋ
Proton Pump Inhibitor â āĻĒā§āϰā§āĻāύ āĻĒāĻžāĻŽā§āĻĒ āĻāύāĻšāĻŋāĻŦāĻŋāĻāϰāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Gastric acid secretion inhibitor â āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄ āύāĻŋāĻāϏāϰāĻŖāϰā§āϧ⧠āĻāώā§āϧāĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Treatment of GERD and erosive oesophagitis.
āĻŦāĻžāĻāϞāĻž: āĻā§āϝāĻžāϏā§āĻā§āϰā§āĻāϏā§āĻĢā§āĻāĻŋā§āĻžāϞ āϰāĻŋāĻĢā§āϞāĻžāĻā§āϏ āĻ āĻāĻžāĻĻā§āϝāύāĻžāϞāĻŋāϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤
7. Why Doctor Prescribed It â āĻā§āύ āĻĻāĻŋā§ā§āĻā§āύ?
Possibly for an undocumented acid-related complaint or empirical gastric acid suppression.
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄāĻāύāĻŋāϤ āĻā§āύ⧠āϏāĻŽāϏā§āϝāĻž āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰ⧠āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Important: No acid-related complaint is written in C/C.
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Diarrhoea, nausea, abdominal discomfort and flatulence.
āĻŦāĻžāĻāϞāĻž: āĻĄāĻžā§āϰāĻŋā§āĻž, āĻŦāĻŽāĻŋāĻāĻžāĻŦ, āĻĒā§āĻā§āϰ āĻ āϏā§āĻŦāϏā§āϤāĻŋ āĻ āĻā§āϝāĻžāϏāĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻāĻ
DDR 30 mg â MedEx Bangladesh
10. Unit Price, Strip Price and Other Forms â āĻĻāĻžāĻŽ āĻ āϧāϰāύ
Unit price: ā§ŗ11.50
Strip price: ā§ŗ115.00.
Other strength: DDR 60 mg.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāϤāĻŋ āĻā§āϝāĻžāĻĒāϏā§āϞ ā§§ā§§.ā§Ģā§Ļ āĻāĻžāĻāĻž āĻāĻŦāĻ ā§§ā§ĻāĻāĻŋāϰ āϏā§āĻā§āϰāĻŋāĻĒ ā§§ā§§ā§Ģ āĻāĻžāĻāĻžāĨ¤
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Inhibits gastric Hâē/Kâē-ATPase in parietal cells.
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄ āĻā§āĻĒāĻžāĻĻāύā§āϰ āĻĒā§āϰāϧāĻžāύ āĻāύāĻāĻžāĻāĻŽāĻā§ āĻŦāĻžāϧāĻž āĻĻā§ā§āĨ¤
12. Drug Indications â āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§?
GERD, erosive oesophagitis and maintenance of healed erosive oesophagitis.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϏāĻŋāĻĄ āϰāĻŋāĻĢā§āϞāĻžāĻā§āϏ, āĻŦā§āĻāĻā§āĻŦāĻžāϞāĻž āĻāĻŦāĻ āĻāĻžāĻĻā§āϝāύāĻžāϞāĻŋāϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄāĻāύāĻŋāϤ āĻā§āώāϤāĨ¤
13. Drug Interactions + Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
Interactions may occur with certain acid-dependent medicines, some antiretrovirals, warfarin and high-dose methotrexate. Avoid in hypersensitivity.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻā§ āĻāώā§āϧā§āϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āĻŦāĻž āϰāĻā§āϤā§āϰ āĻŽāĻžāϤā§āϰāĻžā§ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāĻāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Avoid unnecessary prolonged PPI use. Reassess long-term indication.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§ā§āĻāύ āĻāĻžā§āĻž āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻā§āϝāĻžāϏā§āĻā§āϰāĻŋāĻā§āϰ āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž
30 mg once daily is an established regimen for selected acid-related indications.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ ā§āϝāĻžāϏāĻŋāĻĄāĻāύāĻŋāϤ āϰā§āĻā§ āĻĻā§āύāĻŋāĻ āĻāĻāĻŦāĻžāϰ ā§Šā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž. āĻĻā§āĻā§āĻž āĻšā§āĨ¤
Dexlansoprazole can generally be administered with or without food.
āĻŦāĻžāĻāϞāĻž: āĻāĻ āĻĒā§āϰāϏā§āϤā§āϤāĻŋ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāĻžāĻŦāĻžāϰā§āϰ āϏāĻā§āĻā§ āĻŦāĻž āĻāĻžā§āĻžāĻ āϏā§āĻŦāύ āĻāϰāĻž āϝāĻžā§āĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Use after clinical benefitârisk evaluation.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§ā§āĻāύ āĻ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
Other strengths and alternative formulations exist; a fixed-dose combination is not established on the reviewed DDR page.
āĻŦāĻžāĻāϞāĻž: ā§Šā§Ļ āĻ ā§Ŧā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž. strength āϰā§ā§āĻā§āĨ¤
đ§ Clinical Verdict
No clear documented indication.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻŽā§āϞ āĻ āĻāĻŋāϝā§āĻā§ āĻŦā§āĻāĻā§āĻŦāĻžāϞāĻž āĻŦāĻž āĻ ā§āϝāĻžāϏāĻŋāĻĄāĻāύāĻŋāϤ āϏāĻŽāϏā§āϝāĻž āϞā§āĻāĻž āύā§āĻāĨ¤ āϤāĻžāĻ DDR āĻĻā§āĻā§āĻžāϰ āϏā§āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Drug confidence: 0.99.
Patient-specific indication confidence: 0.35.
Source:
đŠ MEDICINE 4 â CORALCIN-D
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Coral Calcium + Vitamin D3 â āĻā§āϰāĻžāϞ āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻĄāĻŋā§ŠāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Coralcin-D 500 mg + 200 IU Tablet â Renata PLC.
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Other calcium carbonate/coral calcium plus vitamin D preparations are available.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻ āϧāϰāύā§āϰ āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻĄāĻŋ āĻĒā§āϰāϏā§āϤā§āϤāĻŋ āĻĒāĻžāĻā§āĻž āϝāĻžā§, āϤāĻŦā§ elemental calcium-āĻāϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āĻŽāĻŋāϞāĻŋā§ā§ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
4. MedEx Therapeutic Class â āĻŽā§āĻĄāĻāĻā§āϏ āĻļā§āϰā§āĻŖāĻŋ
Specific mineral & vitamin combined preparations.
āĻŦāĻžāĻāϞāĻž: āĻāύāĻŋāĻ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āϏāĻŽāύā§āĻŦāĻŋāϤ āĻĒā§āϰāϏā§āϤā§āϤāĻŋāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Calcium supplement + Cholecalciferol â āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻĄāĻŋ āϏāĻŽā§āĻĒā§āϰāĻāĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Prevention or management of calcium/vitamin D inadequacy and selected bone disorders.
āĻŦāĻžāĻāϞāĻž: āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻĄāĻŋāϰ āĻāĻžāĻāϤāĻŋ āĻāĻŦāĻ āĻāĻŋāĻā§ āĻšāĻžā§ā§āϰ āϰā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤
7. Why Doctor Prescribed It â āĻā§āύ āĻĻāĻŋā§ā§āĻā§āύ?
Possibly for generalized weakness or presumed nutritional inadequacy.
āĻŦāĻžāĻāϞāĻž: āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻŦāĻž āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒā§āώā§āĻāĻŋāϰ āĻāĻžāĻāϤāĻŋāϰ āĻāύā§āϝ āĻĻāĻŋā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
Limitation: Deficiency has not been demonstrated.
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Constipation, gastrointestinal discomfort and hypercalcaemia with excessive intake.
āĻŦāĻžāĻāϞāĻž: āĻā§āώā§āĻ āĻāĻžāĻ āĻŋāύā§āϝ, āĻĒā§āĻā§āϰ āĻ āϏā§āĻŦāϏā§āϤāĻŋ āĻāĻŦāĻ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϰāĻšāĻŖā§ āϰāĻā§āϤ⧠āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻŦā§ā§ā§ āϝāĻžāĻā§āĻžāĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻāĻ
Coralcin-D â MedEx Bangladesh
10. Unit Price, Strip Price and Other Forms â āĻĻāĻžāĻŽ āĻ āϧāϰāύ
Unit price: ā§ŗ11.50
Strip price: ā§ŗ115.00.
Composition: Calcium carbonate 1250 mg, equivalent to elemental calcium 500 mg, with vitamin D3 200 IU.
Other forms: 500 mg + 400 IU and 600 mg + 400 IU preparations.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāϤāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ ā§§ā§§.ā§Ģā§Ļ āĻāĻžāĻāĻž; ā§§ā§ĻāĻāĻŋāϰ āϏā§āĻā§āϰāĻŋāĻĒ ā§§ā§§ā§Ģ āĻāĻžāĻāĻžāĨ¤
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Calcium contributes to mineral homeostasis and bone mineralisation. Vitamin D improves intestinal calcium absorption.
āĻŦāĻžāĻāϞāĻž: āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻšāĻžā§ā§āϰ āĻāύāĻŋāĻ āĻāĻĒāĻžāĻĻāĻžāύ āϏāϰāĻŦāϰāĻžāĻš āĻāϰ⧠āĻāĻŦāĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻĄāĻŋ āĻļāϰā§āϰ⧠āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻļā§āώāĻŖā§ āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
12. Drug Indications â āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§?
Calcium deficiency, selected osteoporosis management, osteomalacia and other deficiency-related conditions.
āĻŦāĻžāĻāϞāĻž: āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽā§āϰ āĻāĻžāĻāϤāĻŋ, āĻ āϏā§āĻāĻŋāĻāĻĒā§āϰā§āϏāĻŋāϏ āĻ āĻ āϏā§āĻāĻŋāĻāĻŽā§āϝāĻžāϞāĻžāϏāĻŋā§āĻžāϏāĻš āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ āĻŦāϏā§āĻĨāĻžā§āĨ¤
13. Drug Interactions + Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
Interactions include reduced absorption of certain antibiotics and levothyroxine. Use cautiously with thiazides and digoxin. Contraindications include hypercalcaemia.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻā§ āĻāώā§āϧā§āϰ āĻļā§āώāĻŖ āĻāĻŽāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϰāĻā§āϤ⧠āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻŦā§āĻļāĻŋ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Assess kidney-stone history, renal function and total calcium/vitamin D intake.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻĄāύāĻŋāϤ⧠āĻĒāĻžāĻĨāϰ, āĻāĻŋāĻĄāύāĻŋāϰ āϰā§āĻ āĻāĻŦāĻ āĻ āύā§āϝ āϏāĻžāĻĒā§āϞāĻŋāĻŽā§āύā§āĻ āĻĨā§āĻā§ āĻāϤ āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āύā§āĻā§āĻž āĻšāĻā§āĻā§ āϤāĻž āϝāĻžāĻāĻžāĻ āĻāϰā§āϰāĻŋāĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž
Dosage depends on indication and dietary intake. Calcium carbonate preparations are generally taken with food.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻ āĻ āĻāĻžāĻĻā§āϝāĻžāĻā§āϝāĻžāϏ āĻ āύā§āϝāĻžā§ā§ āĻŽāĻžāϤā§āϰāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āĻšā§; āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāĻžāĻŦāĻžāϰā§āϰ āϏāĻā§āĻā§ āύā§āĻā§āĻž āĻšā§āĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
May be used for an established nutritional indication with appropriate dosing.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻŽāĻžāϤā§āϰāĻžā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžā§āĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
500/400 IU and 600/400 IU strengths are available.
āĻŦāĻžāĻāϞāĻž: āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻĄāĻŋāϰ āĻŦāĻŋāĻāĻŋāύā§āύ strength āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
đ§ Clinical Verdict
Supplementation is not supported by documented deficiency in this prescription.
āĻŦāĻžāĻāϞāĻž: āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻĨāĻžāĻāϞā§āĻ āĻā§āϝāĻžāϞāϏāĻŋā§āĻžāĻŽā§āϰ āĻāĻžāĻāϤāĻŋ āĻāĻā§âāĻāĻŽāύ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āϏāĻ āĻŋāĻ āύā§āĨ¤
Drug confidence: 0.99.
Patient-specific indication confidence: 0.35.
Source:
đŠ MEDICINE 5 â MURON 2% OINTMENT
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Mupirocin â āĻŽāĻŋāĻāĻĒāĻŋāϰā§āϏāĻŋāύāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Muron 2% Ointment â Drug International Ltd.
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Other mupirocin 2% ointment and cream preparations are available.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ āĻ āύā§āϝ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āĻ cream formulation āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
4. MedEx Therapeutic Class â āĻŽā§āĻĄāĻāĻā§āϏ āĻļā§āϰā§āĻŖāĻŋ
Topical Antibiotic preparations â āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Topical antibacterial agent â āϏā§āĻĨāĻžāύā§ā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāύāĻžāĻļāĻ āĻāώā§āϧāĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Treatment of selected superficial bacterial skin infections.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻāĻĒāϰāĻŋāĻāĻžāĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§āĨ¤
7. Why Doctor Prescribed It â āĻā§āύ āĻĻāĻŋā§ā§āĻā§āύ?
Possibly for bacterial involvement in the genital ulcer.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻžā§ā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžā§ āĻĻāĻŋā§ā§āĻā§āύ āĻŦāϞ⧠āϧāĻžāϰāĻŖāĻž āĻāϰāĻž āϝāĻžā§āĨ¤
Limitation: No pus, discharge or bacterial diagnosis is documented.
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Burning, stinging, erythema, itching and contact dermatitis.
āĻŦāĻžāĻāϞāĻž: āϞāĻžāĻāĻžāύā§āϰ āĻāĻžā§āĻāĻžā§ āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž, āϞāĻžāϞāĻāĻžāĻŦ, āĻā§āϞāĻāĻžāύāĻŋ āĻŦāĻž āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻāĻ
Muron 2% Ointment â MedEx Bangladesh
10. Unit Price, Strip Price and Other Forms â āĻĻāĻžāĻŽ āĻ āϧāϰāύ
10 g tube price: ā§ŗ140.00.
Tablet or strip price is not applicable.
Other forms: Mupirocin cream and ointment.
āĻŦāĻžāĻāϞāĻž: ā§§ā§Ļ āĻā§āϰāĻžāĻŽā§āϰ āĻāĻŋāĻāĻŦ ā§§ā§Ēā§Ļ āĻāĻžāĻāĻžāĨ¤
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Inhibits bacterial isoleucyl-tRNA synthetase and protein synthesis.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻĒā§āϰā§āĻāĻŋāύ āϤā§āϰāĻŋāϰ āĻāύā§āϝ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻāύāĻāĻžāĻāĻŽāĻā§ āĻŦāĻžāϧāĻž āĻĻā§ā§āĨ¤
12. Drug Indications â āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§?
Impetigo, selected folliculitis and superficial bacterial skin infection.
āĻŦāĻžāĻāϞāĻž: āĻāĻŽāĻĒā§āĻāĻžāĻāĻā§, āĻāĻŋāĻā§ āĻĢāϞāĻŋāĻāĻŋāĻāϞāĻžāĻāĻāĻŋāϏ āĻāĻŦāĻ āϏā§āĻĨāĻžāύā§ā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
13. Drug Interactions + Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
Major topical interactions are uncommon. Avoid in known hypersensitivity.
āĻŦāĻžāĻāϞāĻž: āĻāώā§āϧā§āϰ āĻāĻĒāĻžāĻĻāĻžāύ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Avoid inappropriate use on genital mucosal surfaces, eyes or inside the nose unless the formulation and indication are appropriate.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āĻā§āϤāϰā§āϰ āĻļā§āϞā§āώā§āĻŽāĻžāĻāĻŋāϞā§āϞāĻŋ āĻŦāĻž āĻ āĻāĻžāύāĻž āϧāϰāύā§āϰ āĻāĻžā§ā§ āύāĻŋāĻā§āϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ⧠āϞāĻžāĻāĻžāύ⧠āĻāĻāĻŋāϤ āύā§āĨ¤
Prolonged unnecessary use may promote resistant or nonsusceptible organisms.
āĻŦāĻžāĻāϞāĻž: āĻ āĻĒā§āϰā§ā§āĻāύ⧠āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠āĻā§āĻŦāĻžāĻŖā§āϰ āĻĒā§āϰāϤāĻŋāϰā§āϧāĻā§āώāĻŽāϤāĻž āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž
MedEx describes application three times daily for up to 10 days in relevant skin infections.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϤā§āĻŦāĻā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖā§ āϏāϰā§āĻŦā§āĻā§āĻ ā§§ā§Ļ āĻĻāĻŋāύ āĻĒāϰā§āϝāύā§āϤ āĻĻāĻŋāύ⧠āϤāĻŋāύāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϤāĻĨā§āϝ āϰā§ā§āĻā§āĨ¤
Patient-specific concern: If the prescription truly specifies 20 days, the duration requires review.
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Use after benefitârisk evaluation.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§ā§āĻāύ āĻ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻžā§ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
Different topical formulations exist; a relevant fixed combination is not established on the reviewed Muron brand page.
āĻŦāĻžāĻāϞāĻž: ointment āĻ cream formulation āϰā§ā§āĻā§āĨ¤
đ§ Clinical Verdict
Potentially appropriate for bacterial superficial infection, but not definitive treatment for syphilis or herpes.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžā§; āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻž āĻšāĻžāϰāĻĒāĻŋāϏ āϏāĻžāϰāĻžā§ āύāĻžāĨ¤
Drug confidence: 0.99.
Patient-specific indication confidence: 0.55.
Source:
đŠ MEDICINE 6 â SUPRAVIT CAPSULE
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Multivitamin [Adult preparation] â āĻĒā§āϰāĻžāĻĒā§āϤāĻŦā§āϏā§āĻāĻĻā§āϰ āĻŽāĻžāϞā§āĻāĻŋāĻāĻŋāĻāĻžāĻŽāĻŋāύāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Supravit Capsule â Drug International Ltd.
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Other adult multivitamin preparations are available, but their exact vitamin contents may differ.
āĻŦāĻžāĻāϞāĻž: āĻ āύā§āϝ āĻŽāĻžāϞā§āĻāĻŋāĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āĻĒāĻžāĻā§āĻž āĻā§āϞā§āĻ āĻāĻĒāĻžāĻĻāĻžāύ āĻ āĻŽāĻžāϤā§āϰāĻž āĻāĻāĻ āύāĻžāĻ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
4. MedEx Therapeutic Class â āĻŽā§āĻĄāĻāĻā§āϏ āĻļā§āϰā§āĻŖāĻŋ
Specific combined vitamin preparations â āĻāĻāĻžāϧāĻŋāĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āϏāĻŽāύā§āĻŦāĻŋāϤ āĻĒā§āϰāϏā§āϤā§āϤāĻŋāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Multivitamin nutritional supplement â āĻĒā§āώā§āĻāĻŋāĻāϤ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āϏāĻŽā§āĻĒā§āϰāĻāĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Prevention and management of vitamin deficiency.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āĻāĻžāĻāϤāĻŋ āĻĒā§āϰāĻŖ āĻŦāĻž āĻĒā§āϰāϤāĻŋāϰā§āϧāĨ¤
7. Why Doctor Prescribed It â āĻā§āύ āĻĻāĻŋā§ā§āĻā§āύ?
Possibly for weakness or nutritional support.
āĻŦāĻžāĻāϞāĻž: āĻļāĻžāϰā§āϰāĻŋāĻ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻ āĻĒā§āώā§āĻāĻŋāĻāϤ āϏāĻšāĻžā§āϤāĻžāϰ āĻāύā§āϝ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Generally well tolerated at recommended doses; gastrointestinal upset or hypersensitivity can occur.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻŽāĻžāϤā§āϰāĻžā§ āϏāĻžāϧāĻžāϰāĻŖāϤ āϏāĻšāύā§ā§āĨ¤ āĻāĻāύ⧠āĻĒā§āĻā§āϰ āĻ āϏā§āĻŦāϏā§āϤāĻŋ āĻŦāĻž āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻāĻ
Supravit Capsule â MedEx Bangladesh
10. Unit Price, Strip Price and Composition â āĻĻāĻžāĻŽ āĻ āĻāĻĒāĻžāĻĻāĻžāύ
Unit price: ā§ŗ2.05.
Strip price: ā§ŗ30.75 for 15 capsules.
Composition includes: Vitamins A, D3, C, B1, B2, B3, B5, B6, B12 and E.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāϤāĻŋ āĻā§āϝāĻžāĻĒāϏā§āϞ ⧍.ā§Ļā§Ģ āĻāĻžāĻāĻž; ā§§ā§ĢāĻāĻŋāϰ āϏā§āĻā§āϰāĻŋāĻĒ ā§Šā§Ļ.ā§ā§Ģ āĻāĻžāĻāĻžāĨ¤
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Replenishes vitamins needed for normal metabolic and cellular function.
āĻŦāĻžāĻāϞāĻž: āĻļāϰā§āϰā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŦāĻŋāĻĒāĻžāĻ āĻ āĻā§āώā§āϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽā§ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āϏāϰāĻŦāϰāĻžāĻš āĻāϰā§āĨ¤
12. Drug Indications â āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§?
Vitamin deficiency and selected nutritional inadequacy.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āĻāĻžāĻāϤāĻŋ āĻ āĻĒā§āώā§āĻāĻŋāĻāϤ āĻ āĻĒāϰā§āϝāĻžāĻĒā§āϤāϤāĻžā§āĨ¤
13. Drug Interactions + Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
Assess interactions according to the exact vitamin formulation. Avoid in known hypersensitivity.
āĻŦāĻžāĻāϞāĻž: āĻāĻĒāĻžāĻĻāĻžāύ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤ āĻ āύā§āϝ āϏāĻžāĻĒā§āϞāĻŋāĻŽā§āύā§āĻā§āϰ āϏāĻā§āĻā§ āĻŽā§āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āĻŽāĻžāϤā§āϰāĻž āĻšāĻŋāϏāĻžāĻŦ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Avoid excessive intake, especially with multiple supplements containing fat-soluble vitamins.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻžāϧāĻŋāĻ āϏāĻžāĻĒā§āϞāĻŋāĻŽā§āύā§āĻ āĻāĻāϏāĻā§āĻā§ āĻā§āϞ⧠āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻā§āϰāĻšāĻŖā§āϰ āĻā§āĻāĻāĻŋ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž
One capsule daily is the MedEx-listed adult regimen.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒā§āϰāĻžāĻĒā§āϤāĻŦā§āϏā§āĻāĻĻā§āϰ āĻĻā§āύāĻŋāĻ āĻāĻāĻāĻŋ āĻā§āϝāĻžāĻĒāϏā§āϞāĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Use an appropriately selected supplement according to pregnancy or lactation needs.
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύā§āϰ āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻāĻĒāϝā§āĻā§āϤ āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻĒā§āϰāϏā§āϤā§āϤāĻŋ āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšā§āĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
Supravit-G and Supravit-S are different multivitaminâmultimineral formulations, not identical substitutes.
āĻŦāĻžāĻāϞāĻž: Supravit-G āĻ Supravit-S-āĻāϰ āĻāĻĒāĻžāĻĻāĻžāύ āĻāϞāĻžāĻĻāĻž, āϤāĻžāĻ āĻāĻāĻ āĻāώā§āϧ āĻŽāύ⧠āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
đ§ Clinical Verdict
Supportive nutritional therapy, not definitive treatment for genital ulcer disease.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āώā§āĻāĻŋāϰ āĻāĻžāĻāϤāĻŋāϤ⧠āϏāĻšāĻžā§āĻ; āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āĻŦāĻž STI-āĻāϰ āĻŽā§āϞ āĻāĻŋāĻāĻŋā§āϏāĻž āύā§āĨ¤
Drug confidence: 0.99.
Patient-specific indication confidence: 0.45.
Source:
đ§ SECTION 11. BANGLADESH DRUG COMPARISON TABLE
Table 2 â Disease-Specific Common Drug Options
Important: The following table presents examples of Bangladesh-listed drugs for relevant confirmed conditions. It is not a recommendation to give every medicine to this patient.
| No. | Disease/Condition | Generic | Bangladesh Example | Why Used |
|---|---|---|---|---|
| 1 | Primary/secondary syphilis | Benzathine benzylpenicillin | Benzapen | First-line penicillin treatment |
| 2 | Genital herpes | Acyclovir | Acerux, Clovir, Simplovir, Virux | Inhibits HSV replication |
| 3 | Genital herpes | Valacyclovir | Available valacyclovir preparations | Alternative systemic antiviral |
| 4 | Superficial bacterial infection | Mupirocin | Muron | Local antibacterial treatment |
| 5 | Selected bacterial skin infections | Cephalexin | Available cephalexin preparations | Oral antibacterial treatment when indicated |
| 6 | Confirmed fungal balanitis | Clotrimazole | Clotrim | Topical antifungal treatment |
| 7 | Severe resistant Gram-positive infection | Linezolid | Linzolid | Restricted systemic antibacterial treatment |
| 8 | Allergic/pruritic rash | Fexofenadine | Fenadin | Symptom relief only |
āĻŦāĻžāĻāϞāĻž: āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āĻāϏāĻŦ āϰā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻŦāĻŋāĻāĻŋāύā§āύ āĻā§āύā§āϰāĻŋāĻ āĻ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§āĨ¤ āĻāĻŋāύā§āϤ⧠āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻāĻžā§āĻž āĻāĻāϏāĻā§āĻā§ āϏāĻŦ āĻāώā§āϧ āĻĻā§āĻā§āĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Relevant Guideline Regimens
Early syphilis: Benzathine penicillin G 2.4 million units IM, once for appropriately staged primary or secondary syphilis.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻŦāĻž āϏā§āĻā§āύā§āĻĄāĻžāϰāĻŋ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠āĻŦā§āύāĻāĻžāĻĨāĻŋāύ āĻĒā§āύāĻŋāϏāĻŋāϞāĻŋāύ āĻāĻŋ ⧍ā§Ē āϞāĻā§āώ āĻāĻāύāĻŋāĻ āĻāĻāĻŦāĻžāϰ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϤ⧠āĻĻā§āĻā§āĻž āĻšā§āĨ¤
Late latent/unknown-duration syphilis: Different staging and treatment duration apply; the early-syphilis single-dose regimen must not be assumed sufficient.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻŽā§ā§āĻžāĻĻ āĻ āĻāĻžāύāĻž āĻŦāĻž āĻĻā§āϰāĻŋāϤ⧠āĻļāύāĻžāĻā§āϤ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧠āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻŽā§ā§āĻžāĻĻ āĻāϞāĻžāĻĻāĻžāĨ¤
First episode genital herpes: Acyclovir 400 mg orally three times daily for 7â10 days, or an equivalent recommended antiviral regimen.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻĨāĻŽāĻŦāĻžāϰā§āϰ āĻā§āύāĻŋāĻāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϏāĻŽā§ā§āϰ āĻāύā§āϝ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻāĻžāĻāϰāĻžāϞ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
These are guideline reference regimens for confirmed or clinically strongly suspected disease, not an automatically applicable new prescription for this patient.
Evidence: CDC STI Treatment Guidelines.
Confidence in general guideline regimens: 0.99.
đŠ SECTION 12. DOCTOR’S Dx VS LIPU MED Dx COMPARISON
đ§ Doctor’s Documented Diagnosis
No definitive diagnosis is written in the prescription.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āϏāϰāĻžāϏāϰāĻŋ āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ āύāĻžāĻŽ āϞā§āĻā§āύāύāĻŋāĨ¤
Confidence: 0.99.
đ§ Doctor’s Possible Diagnostic Considerations
- Syphilis: VDRL was ordered â āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻŋāĻŦā§āĻāύāĻžā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Bacterial infection: Linezolid and mupirocin were prescribed â āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ āϏāύā§āĻĻā§āĻš āĻāϰāĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Allergic/pruritic component: Fexofenadine was prescribed â āĻā§āϞāĻāĻžāύāĻŋ āĻŦāĻž āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻžā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Nutritional inadequacy: Calcium and multivitamin were prescribed â āĻĒā§āώā§āĻāĻŋāĻāϤ āϏāĻšāĻžā§āϤāĻž āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.50â0.85 for inferred clinical intentions.
đŠ LIPU MED Working Diagnosis
Undifferentiated Genital Ulcer Disease with Skin Rash â Rule Out Syphilis and Genital Herpes.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§ āĻāĻž āĻ āĻļāϰā§āϰ⧠āϰâā§āϝāĻžāĻļ; āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ āĻšāĻžāϰāĻĒāĻŋāϏ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.99 for the clinical syndrome.
đŠ Similarities â āĻŽāĻŋāϞ
- VDRL investigation is consistent with considering syphilis.
- Both the original treatment choices and this assessment consider infectious causes.
- Skin symptoms are clinically relevant in both assessments.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰā§āĻā§āώāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļ āĻ āĻāώā§āϧā§āϰ āϧāϰāύ āĻĻā§āĻā§ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŦāĻŋāĻŦā§āĻāύāĻžāϰ āĻāĻā§āĻāĻŋāϤ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
đ§ Differences â āĻ āĻŽāĻŋāϞ
- No physician-documented etiological diagnosis exists.
- HSV evaluation is not recorded in the original prescription.
- Linezolid requires stronger evidence of bacterial infection.
- The original note lacks lesion morphology and focused sexual-health history.
- Syphilis confirmatory testing and HIV screening are not recorded.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻ āϰā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āύāĻžāĻŽ āϞā§āĻā§āύāύāĻŋ; HSV āĻĒāϰā§āĻā§āώāĻž, āĻā§āώāϤā§āϰ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻžāϰ āϤāĻĨā§āϝāĻ āύā§āĻāĨ¤
Final Comparison
The evaluations are partially aligned regarding investigation of syphilis, but there is no documented physician diagnosis to establish diagnostic equivalence.
āĻŦāĻžāĻāϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻŋāĻŦā§āĻāύāĻžāϰ āĻā§āώā§āϤā§āϰ⧠āĻŽāĻŋāϞ āϰā§ā§āĻā§āĨ¤ āϤāĻŦā§ āĻāĻŋāĻāĻŋā§āϏāĻ Dx āύāĻž āϞā§āĻāĻžā§ āĻĻā§āĻāĻāĻŋ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻāĻāĻ āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.99.
đŠē SECTION 13. TEN CLINICAL DECISION-MAKING MODULES
đŠ MODULE 1 â CLINICAL DECISION-MAKING ALGORITHM
English Meaning: A structured sequence of clinical decisions used to identify the likely disease and guide treatment.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϧāĻžāĻĒā§ āϧāĻžāĻĒā§ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻā§āĻžāϰ āĻĒāĻĻā§āϧāϤāĻŋāĨ¤
Clinical Application
Genital ulcer â Focused examination â Evaluate syphilis/HSV and noninfectious causes â Obtain indicated tests â Determine need for same-day presumptive treatment â Review results and follow-up.
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āĻĒā§āϰāĻĨāĻŽā§ āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āϤāĻžāϰāĻĒāϰ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ āĻ āĻĨāĻŦāĻž āĻ āύā§āϝ āϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻĻā§āĻā§ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Patient-Specific Assessment
This patient has genital ulceration and rash, but no documented lesion morphology or laboratory results.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āϝā§āύāĻžāĻā§āĻā§ āĻāĻž āĻ āϰâā§āϝāĻžāĻļ āĻāĻā§, āĻāĻŋāύā§āϤ⧠āĻāĻžā§ā§āϰ āϧāϰāύ āĻŦāĻž āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻāĻžāύāĻž āύā§āĻāĨ¤
Evidence
CDC advises laboratory evaluation of genital ulcers and appropriate presumptive treatment when infectious syphilis or first-episode herpes is suspected.
āĻŦāĻžāĻāϞāĻž: āĻā§āϰāĻžāϞ⧠āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāύā§āĻĻā§āĻš āĻĨāĻžāĻāϞ⧠āĻĒā§āϰā§ā§āĻāύā§ā§ āύāĻŽā§āύāĻž āϏāĻāĻā§āϰāĻšā§āϰ āĻĒāϰ āĻāĻāĻ āĻĻāĻŋāύ⧠āĻāĻŋāĻāĻŋā§āϏāĻž āĻļā§āϰ⧠āĻāϰāĻžāϰ āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.98.
đŠ MODULE 2 â DIAGNOSTIC EVIDENCE & UNCERTAINTY
English Meaning: Assessment of which findings support a diagnosis and which missing data limit certainty.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻĒāĻā§āώ⧠āĻā§ āĻĒā§āϰāĻŽāĻžāĻŖ āĻāĻā§ āĻāĻŦāĻ āĻā§āύ āϤāĻĨā§āϝā§āϰ āĻ āĻāĻžāĻŦā§ āύāĻŋāĻļā§āĻāĻŋāϤ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āϏāĻŽā§āĻāĻŦ āύā§āĨ¤
Clinical Application
Separate confirmed symptoms from suspected disease causes.
Patient-Specific Assessment
Confirmed as documented complaints: Genital ulcer, rash, weakness.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§ āĻāĻž, āϰâā§āϝāĻžāĻļ āĻ āĻĻā§āϰā§āĻŦāϞāϤāĻžāϰ āĻ āĻāĻŋāϝā§āĻ āϞā§āĻāĻž āĻāĻā§āĨ¤
Unconfirmed: Syphilis, herpes, bacterial infection.
āĻŦāĻžāĻāϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ āĻ āĻĨāĻŦāĻž āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšā§āύāĻŋāĨ¤
Evidence Gap
No RPR/VDRL result, treponemal test, HSV PCR or focused lesion examination is available.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻ āĻāĻžā§ā§āϰ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āĻĒāϰā§āĻā§āώāĻž āύā§āĻāĨ¤
Diagnostic Confidence
- Clinical syndrome: 0.99
- Syphilis differential relevance: 0.70
- HSV differential relevance: 0.65
- Secondary bacterial infection: 0.50
Important: These confidence values are qualitative judgments, not validated disease probabilities.
đŠ MODULE 3 â PRESCRIPTION SAFETY AUDIT
English Meaning: Systematic evaluation of medicine indication, dose, duration, interactions and monitoring.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻāώā§āϧ āĻā§āύ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§, āĻāϤāĻĻāĻŋāύ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§ āĻāĻŦāĻ āĻāϤāĻāĻž āύāĻŋāϰāĻžāĻĒāĻĻ āϤāĻž āϝāĻžāĻāĻžāĻāĨ¤
Clinical Application
Review all six medicines individually and identify avoidable risks.
Patient-Specific Assessment
| Drug | Safety Concern | Priority |
|---|---|---|
| Linezolid | Potentially prolonged use without documented bacterial indication; CBC monitoring | High |
| Fexofenadine | Confirm itching/allergic indication and renal status | Moderate |
| Dexlansoprazole | Acid-related indication not documented | Moderate |
| Coralcin-D | Deficiency not documented | LowâModerate |
| Mupirocin | Verify lesion type and duration | Moderate |
| Supravit | Supportive therapy only; avoid unnecessary duplication | Low |
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āϏāĻŦāĻā§ā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāώ⧠āĻšāϞ⧠LinezolidāĨ¤ āĻāĻāĻŋ āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻāĨ¤ āĻ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻŦāĻž āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧠āϰāĻā§āϤā§āϰ āĻā§āώ āĻ āĻĒā§āϞā§āĻāϞā§āĻ āĻāĻŽāĻžāϰ āĻŽāϤ⧠āϏāĻŽāϏā§āϝāĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Evidence
MedEx linezolid monograph recommends weekly CBC monitoring, particularly with treatment beyond two weeks.
Confidence: 0.99 for linezolid monitoring concern.
đŠ MODULE 4 â RED FLAGS & EMERGENCY REFERRAL
English Meaning: Identification of symptoms that may indicate serious disease or need urgent specialist/hospital evaluation.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻŦāĻŋāĻĒāĻā§āĻāύāĻ āϞāĻā§āώāĻŖ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž, āϝāĻžāϤ⧠āĻāϰā§āϰāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĻā§āĻā§āĻž āϝāĻžā§āĨ¤
Red Flags
Severe genital pain or swelling â āϝā§āύāĻžāĻā§āĻā§ āĻĒā§āϰāĻāĻŖā§āĻĄ āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻĢā§āϞāĻžāĨ¤
Rapidly spreading redness â āĻĻā§āϰā§āϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻā§āĻŋā§ā§ āĻĒā§āĻžāĨ¤
High fever or systemic toxicity â āĻāĻā§āĻ āĻā§āĻŦāϰ āĻŦāĻž āĻā§āϰā§āϤāϰ āĻ āϏā§āϏā§āĻĨāϤāĻžāĨ¤
Urinary retention â āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻāĻāĻā§ āϝāĻžāĻā§āĻžāĨ¤
Tissue necrosis â āĻāĻŋāϏā§āϝ⧠āĻāĻžāϞ⧠āĻšā§ā§ āύāώā§āĻ āĻšāĻā§āĻžāĨ¤
Visual, auditory or neurological symptoms â āĻā§āĻ, āĻāĻžāύ āĻŦāĻž āϏā§āύāĻžā§ā§āϰ āύāϤā§āύ āϏāĻŽāϏā§āϝāĻžāĨ¤
Patient-Specific Assessment
None of these red flags is documented; however, absence of documentation does not prove absence of the symptom.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϏāĻŦ āĻŦāĻŋāĻĒāĻā§āĻāύāĻ āϞāĻā§āώāĻŖ āϞā§āĻāĻž āύā§āĻāĨ¤ āĻāĻŋāύā§āϤ⧠āϰā§āĻā§āϰ āĻāϏāĻŦ āϞāĻā§āώāĻŖ āύā§āĻâāĻāĻŽāύ āύāĻŋāĻļā§āĻā§āϤāĻž āĻĻā§āĻā§āĻž āϝāĻžā§ āύāĻžāĨ¤
Referral
Emergency department if acute severe infection or systemic deterioration is suspected.
āĻŦāĻžāĻāϞāĻž: āĻā§āϰā§āϤāϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϞāĻā§āώāĻŖ āĻĨāĻžāĻāϞ⧠āĻāϰā§āϰāĻŋ āĻŦāĻŋāĻāĻžāĻā§ āĻĒāĻžāĻ āĻžāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98.
đŠ MODULE 5 â EVIDENCE-BASED TREATMENT COMPARISON
English Meaning: Comparison of prescribed management with disease-specific guideline recommendations.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĻā§āĻā§āĻž āĻāώā§āϧ āĻāύā§āϤāϰā§āĻāĻžāϤāĻŋāĻ āĻāĻžāĻāĻĄāϞāĻžāĻāύā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻā§āĻā§ āĻāϤāĻāĻž āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖ āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Clinical Application
Determine whether treatment targets the underlying cause or merely symptoms.
Patient-Specific Assessment
Linezolid: May treat appropriate bacterial infections, but not the recommended treatment for syphilis or HSV.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻāĻžāϰā§āϝāĻāϰ āĻšāϤ⧠āĻĒāĻžāϰā§, āĻāĻŋāύā§āϤ⧠āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻž āĻšāĻžāϰāĻĒāĻŋāϏā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻž āύā§āĨ¤
Fexofenadine: Symptomatic relief only.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻŦāĻž āĻā§āϞāĻāĻžāύāĻŋ āĻāĻŽāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
Mupirocin: Only appropriate when a relevant superficial bacterial infection exists.
āĻŦāĻžāĻāϞāĻž: āϏā§āĻĨāĻžāύā§ā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖ āĻĨāĻžāĻāϞ⧠āĻāĻĒāĻāĻžāϰā§āĨ¤
Other medicines: Supportive or unrelated to the principal genital-ulcer differential.
āĻŦāĻžāĻāϞāĻž: āĻ āύā§āϝ āĻāώā§āϧāĻā§āϞ⧠āĻŽā§āϞ āϏāĻŽā§āĻāĻžāĻŦā§āϝ STI-āĻāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻž āύā§āĨ¤
Evidence
CDC syphilis and HSV guidance specifies disease-specific antibiotic and antiviral regimens.
Confidence: 0.99.
đŠ MODULE 6 â FOLLOW-UP & CLINICAL OUTCOMES
English Meaning: Scheduled reassessment of symptom resolution, adverse effects and treatment success.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĒāϰ⧠āϰā§āĻā§ āĻāϤāĻāĻž āϏā§āϏā§āĻĨ āĻšāĻā§āĻā§āύ āĻ āĻā§āύ⧠āĻāĻāĻŋāϞāϤāĻž āĻšāĻā§āĻā§ āĻāĻŋ āύāĻž āϤāĻž āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖāĨ¤
Clinical Application
Reassess lesion healing, rash progression and treatment adverse effects.
Patient-Specific Follow-up Plan
Early clinical review: Prompt review after diagnostic testing and examination, with earlier reassessment if symptoms worsen.
āĻŦāĻžāĻāϞāĻž: āĻĒāϰā§āĻā§āώāĻž āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤā§āϰ āĻĒāϰ āĻĻā§āϰā§āϤ āĻĢāϞā§āĻāĻĒ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
If linezolid is being taken: Review CBC/platelets and adverse effects; do not wait until the end of a prolonged course.
āĻŦāĻžāĻāϞāĻž: Linezolid āĻāĻžāϞ⧠āĻĨāĻžāĻāϞ⧠CBC āĻ āĻĒā§āϞā§āĻāϞā§āĻāϏāĻš āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāϰā§āϰāĻŋāĨ¤
If early syphilis is diagnosed and treated: CDC recommends clinical and serological review at 6 and 12 months in the standard adult pathway, adjusted for clinical circumstances.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻŦāĻž āϏā§āĻā§āύā§āĻĄāĻžāϰāĻŋ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĒāϰ⧠āϏāĻžāϧāĻžāϰāĻŖāϤ ā§Ŧ āĻ ā§§ā§¨ āĻŽāĻžāϏ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰāĻā§āϤāĻĒāϰā§āĻā§āώāĻžāϏāĻš āĻĢāϞā§āĻāĻĒ āĻĒā§āϰā§ā§āĻāύāĨ¤
If genital HSV is diagnosed: Reassess healing and recurrence, with further treatment decisions according to clinical presentation.
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāϰāĻĒāĻŋāϏ āĻšāϞ⧠āĻāĻž āĻļā§āĻāĻžāĻā§āĻā§ āĻāĻŋ āύāĻž āĻāĻŦāĻ āĻāĻŦāĻžāϰ āĻšāĻā§āĻā§ āĻāĻŋ āύāĻž āĻĻā§āĻāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.97.
đŠ MODULE 7 â INVESTIGATION INTERPRETATION
English Meaning: Interpretation of diagnostic test results in their clinical context.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āϰā§āĻā§āϰ āϞāĻā§āώāĻŖā§āϰ āϏāĻā§āĻā§ āĻŽāĻŋāϞāĻŋā§ā§ āϏāĻ āĻŋāĻ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻā§āĻžāĨ¤
VDRL/RPR and Treponemal Test Interpretation
| Result Pattern | Possible Meaning | āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž |
|---|---|---|
| RPR/VDRL reactive + treponemal reactive | Supports syphilis infection; stage and treatment history need assessment | āϏāĻŋāĻĢāĻŋāϞāĻŋāϏā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻĒāĻā§āώā§, āϤāĻŦā§ āĻŦāϰā§āϤāĻŽāĻžāύ āύāĻž āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύ |
| RPR/VDRL nonreactive + treponemal reactive | Previous treated infection, early infection or other possibilities | āĻāĻā§ āĻāĻŋāĻāĻŋā§āϏāĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰ⧠āĻ āĻĨāĻŦāĻž āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āϏāĻāĻā§āϰāĻŽāĻŖāĻ āĻšāϤ⧠āĻĒāĻžāϰ⧠|
| RPR/VDRL reactive + treponemal nonreactive | Biological false-positive or discordant result; further evaluation needed | āĻā§āϞ positive āĻŦāĻž āĻĒāϰā§āĻā§āώāĻžāϰ āĻ āĻŽāĻŋāϞ āĻšāϤ⧠āĻĒāĻžāϰ⧠|
| Both nonreactive | Syphilis less likely, but very early infection may not be excluded | āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āϏāĻāĻā§āϰāĻŽāĻŖ āĻĒā§āϰā§āĻĒā§āϰāĻŋ āĻŦāĻžāĻĻ āϝāĻžā§ āύāĻž |
| HSV PCR positive from lesion | Supports genital HSV infection | āĻšāĻžāϰāĻĒāĻŋāϏ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻĒāĻā§āώ⧠|
| HSV PCR negative | Does not fully exclude HSV, particularly in older/healing lesions | āĻĒā§āϰā§āύ⧠āĻŦāĻž āĻļā§āĻāĻŋā§ā§ āĻāϏāĻž āĻāĻžā§ā§āĻ negative āĻšāϤ⧠āĻĒāĻžāϰ⧠|
Patient-Specific Assessment
No investigation results are available.
āĻŦāĻžāĻāϞāĻž: āĻāĻ āϰā§āĻā§āϰ CBC, VDRL āĻŦāĻž HSV āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻĻā§āĻā§āĻž āĻšā§āύāĻŋāĨ¤
Confidence: 0.99 for general interpretation principles.
Evidence: CDC Laboratory Recommendations, 2024.
đŠ MODULE 8 â PATIENT EDUCATION IN BANGLA
English Meaning: Clear communication about the condition, tests, treatment and prevention.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϰā§āĻā§āĻā§ āϏāĻšāĻ āĻāĻžāώāĻžā§ āϤāĻžāĻāϰ āϰā§āĻ, āĻĒāϰā§āĻā§āώāĻž, āĻāĻŋāĻāĻŋā§āϏāĻž āĻ āϏāϤāϰā§āĻāϤāĻž āĻŦā§āĻāĻžāύā§āĨ¤
Patient Education
1. āĻāĻž āĻŽāĻžāύā§āĻ āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āϰā§āĻ āύā§āĨ¤ āϝā§āύāĻžāĻā§āĻā§ āĻāĻž āĻŦāĻŋāĻāĻŋāύā§āύ āĻāĻžāϰāĻŖā§ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
2. āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻāĻŦāĻ āĻšāĻžāϰāĻĒāĻŋāϏ āĻĒāϰā§āĻā§āώāĻž āĻāϰāĻž āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤ āĻļā§āϧ⧠āĻāĻž āĻĻā§āĻā§ āϰā§āĻ āύāĻŋāϰā§āĻŖā§ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
3. āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āύāĻž āĻāϏāĻž āĻĒāϰā§āϝāύā§āϤ āĻāĻžā§ā§āϰ āĻāĻžāϰāĻŖ āύāĻŋāĻļā§āĻāĻŋāϤ āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
4. āĻĒā§āϰā§ā§āĻāύ āĻāĻžā§āĻž āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ āĻāĻžāĻā§āĻž āĻŦāĻž āĻā§āώāϤ⧠āύāĻžāύāĻž āϧāϰāύā§āϰ āĻā§āϰāĻŋāĻŽ āϞāĻžāĻāĻžāύ⧠āĻāĻāĻŋāϤ āύā§āĨ¤
5. āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āĻĨāĻžāĻāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŽā§āϞā§āϝāĻžā§āύ āĻ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻāĻŋāĻāĻŋā§āϏāĻž āĻļā§āώ āύāĻž āĻšāĻā§āĻž āĻĒāϰā§āϝāύā§āϤ āϝā§āύāϏāĻŽā§āĻĒāϰā§āĻ āĻā§āĻžāύ⧠āĻāĻāĻŋāϤāĨ¤
6. āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻļāύāĻžāĻā§āϤ āĻšāϞ⧠āϏāĻā§āĻā§āϰ āĻĒāϰā§āĻā§āώāĻž āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
7. āĻā§āĻŦāϰ, āĻĒā§āϰāĻāĻŖā§āĻĄ āĻŦā§āϝāĻĨāĻž, āĻĢā§āϞāĻž āĻ āĻĨāĻŦāĻž āĻāĻž āĻĻā§āϰā§āϤ āĻā§āĻŋā§ā§ āĻā§āϞ⧠āĻāϰā§āϰāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
8. āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āĻ āύā§āϝāĻžā§ā§ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāϏāĻš āĻĢāϞā§āĻāĻĒ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Patient-Specific Assessment
The patient should receive confidential STI counselling and clear instructions about testing, follow-up and antibiotic safety.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āĻā§ āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āĻā§āĻĒāύā§ā§āϤāĻž āĻŦāĻāĻžā§ āϰā§āĻā§ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰāĻžāĻŽāϰā§āĻļ āĻĻā§āĻā§āĻž āĻāĻāĻŋāϤāĨ¤
Confidence: 0.99.
đŠ MODULE 9 â GUIDELINE UPDATE & EVIDENCE QUALITY
English Meaning: Review of the most relevant available guidelines and assessment of the strength and applicability of evidence.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻŦāϰā§āϤāĻŽāĻžāύ āϝāĻžāĻāĻžāĻāĻā§āϤ āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻ āĻāĻŦā§āώāĻŖāĻžāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻāϤāĻāĻž āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Guideline Sources
CDC STI Treatment Guidelines, 2021
Relevant to genital ulcer evaluation, syphilis and genital herpes.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž, āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ āĻšāĻžāϰāĻĒāĻŋāϏā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
CDC Laboratory Recommendations for Syphilis Testing, 2024
Relevant to interpretation of syphilis serology.
āĻŦāĻžāĻāϞāĻž: VDRL/RPR āĻ treponemal test-āĻāϰ āϏāĻ āĻŋāĻ āĻŦā§āϝāĻžāĻā§āϝāĻžāĨ¤
WHO Guidelines for Management of Symptomatic STIs, 2021
Relevant to syndromic management, including resource-limited settings.
āĻŦāĻžāĻāϞāĻž: āĻĒāϰā§āĻā§āώāĻžāϰ āϏā§āϝā§āĻ āϏā§āĻŽāĻŋāϤ āĻšāϞ⧠āĻāĻĒāϏāϰā§āĻāĻāĻŋāϤā§āϤāĻŋāĻ STI āĻŦā§āϝāĻŦāϏā§āĻĨāĻžāĻĒāύāĻžāĨ¤
NIH Syphilis Guidance, updated 27 May 2026
Provides updated syphilis information, especially in the context of HIV care.
āĻŦāĻžāĻāϞāĻž: HIV-āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏā§āϰ āĻŽā§āϞā§āϝāĻžā§āύ āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϤāĻĨā§āϝāĨ¤
Evidence Quality Assessment
| Evidence | Quality/Appplicability | Confidence |
|---|---|---|
| CDC laboratory testing recommendations | High applicability to diagnostic interpretation | 0.99 |
| CDC syphilis/HSV treatment guidance | High applicability to disease-specific management | 0.99 |
| WHO syndromic STI management | High relevance in resource-limited settings | 0.98 |
| MedEx brand monographs | Useful for Bangladesh brand/pricing; not sufficient alone for prescribing decisions | 0.98 |
| Prescription alone | Limited evidence for etiological diagnosis | 0.99 |
Critical Evidence Limitation
No patient-specific laboratory confirmation exists in the supplied material.
āĻŦāĻžāĻāϞāĻž: āĻāύā§āϤāϰā§āĻāĻžāϤāĻŋāĻ āĻāĻžāĻāĻĄāϞāĻžāĻāύ āϝāϤ āĻļāĻā§āϤāĻŋāĻļāĻžāϞā§āĻ āĻšā§āĻ, āĻāĻ āϰā§āĻā§āϰ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻāĻžā§āĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Overall confidence: 0.99.
Sources:
đŠ MODULE 10 â MEDICAL SEO & ARTICLE TRANSPARENCY
English Meaning: Accurate presentation of medical information for publication, with transparent evidence, uncertainty and authorship.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻāĻŋāĻāĻŋā§āϏāĻžāĻŦāĻŋāώā§āĻ āϤāĻĨā§āϝ āύāĻŋāϰā§āĻā§āϞāĻāĻžāĻŦā§ āĻĒā§āϰāĻāĻžāĻļ āĻāϰāĻž, āĻāĻŦā§āώāĻŖāĻžāϰ āϏā§āϤā§āϰ āĻĻā§āĻā§āĻž āĻāĻŦāĻ āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻŦāĻŋāώ⧠āϏā§āĻĒāώā§āĻ āϰāĻžāĻāĻžāĨ¤
SEO Title
Genital Ulcer with Skin Rash: Syphilis vs Genital Herpes â Diagnosis, Tests and Treatment | LIPU MED
āĻŦāĻžāĻāϞāĻž SEO āĻļāĻŋāϰā§āύāĻžāĻŽ
āϝā§āύāĻžāĻā§āĻā§ āĻāĻž āĻ āĻļāϰā§āϰ⧠āϰâā§āϝāĻžāĻļ: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āύāĻžāĻāĻŋ āĻšāĻžāϰāĻĒāĻŋāϏ? āϰā§āĻāύāĻŋāϰā§āĻŖā§, āĻĒāϰā§āĻā§āώāĻž āĻ āĻāĻŋāĻāĻŋā§āϏāĻž
Meta Description
A bilingual, evidence-based clinical review of genital ulcer disease with skin rash, including syphilis and herpes differential diagnosis, diagnostic testing, MedEx medication review and guideline-based management.
āĻŦāĻžāĻāϞāĻž Meta Description
āϝā§āύāĻžāĻā§āĻā§ āĻāĻž āĻ āϤā§āĻŦāĻā§āϰ āϰâā§āϝāĻžāĻļā§āϰ āĻāĻžāϰāĻŖ, āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ āĻšāĻžāϰāĻĒāĻŋāϏā§āϰ āĻĒāĻžāϰā§āĻĨāĻā§āϝ, āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻž, āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻāĻŦāĻ āĻāĻžāĻāĻĄāϞāĻžāĻāύāĻāĻŋāϤā§āϤāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
Suggested SEO Keywords
Genital Ulcer Disease, Syphilis, Genital Herpes, VDRL, Skin Rash, Linezolid, Mupirocin, STI Bangladesh, LIPU MED.
Transparency Statement
This article is based on one handwritten prescription. The reported symptoms are documented, but a definitive etiological diagnosis has not been established.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāϤāĻŋāĻŦā§āĻĻāύāĻāĻŋ āĻāĻāĻāĻŋ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĨā§āĻā§ āϤā§āϰāĻŋāĨ¤ āϰā§āĻā§āϰ āĻ āĻāĻŋāϝā§āĻ āϞā§āĻāĻž āĻĨāĻžāĻāϞā§āĻ āϰā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āĻāĻāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
Patient Privacy
Before publishing identifiable patient information, obtain documented consent and comply with applicable privacy requirements.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āϤāĻĨā§āϝ āĻĒā§āϰāĻāĻžāĻļā§āϰ āĻāĻā§ āϤāĻžāĻāϰ āϞāĻŋāĻāĻŋāϤ āϏāĻŽā§āĻŽāϤāĻŋ āĻĒā§āϰā§ā§āĻāύāĨ¤
Clinical SEO Confidence
0.98 for accuracy of proposed terminology and transparent presentation.
đ§ SECTION 14. EVIDENCE-BASED MANAGEMENT / TREATMENT
Step 1 â Focused Clinical Examination
Perform appropriate genital, skin and lymph-node examination.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž, āϤā§āĻŦāĻā§āϰ āϰâā§āϝāĻžāĻļ āĻāĻŦāĻ āĻā§āĻāĻāĻāĻŋāϰ āϞāĻŋāĻŽā§āĻĢ āύā§āĻĄ āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.99.
Step 2 â Diagnostic Testing
Obtain syphilis serology, treponemal confirmation, HSV testing and HIV screening as clinically indicated.
āĻŦāĻžāĻāϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ āĻ HIV-āĻāϰ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98.
Step 3 â Decide Whether Presumptive Treatment Is Needed
When clinical suspicion for infectious syphilis or first-episode genital HSV is sufficiently strong, guidelines support prompt clinician-directed presumptive treatment following appropriate specimen collection.
āĻŦāĻžāĻāϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻž āĻĒā§āϰāĻĨāĻŽāĻŦāĻžāϰā§āϰ āĻšāĻžāϰāĻĒāĻŋāϏā§āϰ āĻā§āϰāĻžāϞ⧠āϏāύā§āĻĻā§āĻš āĻĨāĻžāĻāϞ⧠āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻž āύā§āĻā§āĻžāϰ āĻĒāϰ āϰāĻŋāĻĒā§āϰā§āĻā§āϰ āĻāύā§āϝ āĻ āϝāĻĨāĻž āĻ āĻĒā§āĻā§āώāĻž āύāĻž āĻāϰ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻļā§āϰ⧠āĻāϰāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
Confidence: 0.98.
Step 4 â Review Antibiotic Use
Reassess linezolid indication, dosage, duration and safety monitoring.
āĻŦāĻžāĻāϞāĻž: Linezolid āϏāϤā§āϝāĻŋāĻ āĻĒā§āϰā§ā§āĻāύ āĻāĻŋ āύāĻž āĻāĻŦāĻ āĻāϤāĻĻāĻŋāύ āύāĻŋāϰāĻžāĻĒāĻĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāĻŦā§ āϤāĻž āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.99.
Step 5 â Follow-up
Review results, lesion healing, adverse effects and need for specialist care.
āĻŦāĻžāĻāϞāĻž: āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ, āĻāĻž āĻļā§āĻāĻžāύā§āϰ āĻ āĻā§āϰāĻāϤāĻŋ āĻāĻŦāĻ āĻāώā§āϧā§āϰ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98.
đ§ SECTION 15. SAMPLE CLINICAL PRESCRIPTION / CASE NOTE
EDUCATIONAL DEMONSTRATION â NOT A VALID SIGNED PRESCRIPTION
Patient Name: Nazem Ali
Age: 52 years
Sex: Male
Weight: 65 kg
Original Consultation Date: 20 October 2026
C/C
- Generalized weakness â āϏāĻžāϰā§āĻŦāĻŋāĻ āĻĻā§āϰā§āĻŦāϞāϤāĻžāĨ¤
- Genital ulcer â āϝā§āύāĻžāĻā§āĻā§ āĻāĻžāĨ¤
- Skin rash â āϤā§āĻŦāĻā§ āϰâā§āϝāĻžāĻļāĨ¤
O/E
Original O/E: NAD.
BP: Approximately 130/80 mmHg.
Genital examination: Not documented.
Skin examination: Not documented.
Lymph-node examination: Not documented.
Dx
1. Undifferentiated Genital Ulcer Disease (GUD).
2. Associated Cutaneous Rash.
3. Generalized Weakness.
4. R/O Syphilis and Genital HSV Infection.
5. ?Secondary Superficial Bacterial Infection.
āĻŦāĻžāĻāϞāĻž Dx
ā§§. āĻāĻžāϰāĻŖ āĻ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻžāĨ¤
⧍. āϏāĻā§āĻā§ āϤā§āĻŦāĻā§āϰ āϰâā§āϝāĻžāĻļāĨ¤
ā§Š. āϏāĻžāϰā§āĻŦāĻŋāĻ āĻĻā§āϰā§āĻŦāϞāϤāĻžāĨ¤
ā§Ē. āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ āĻšāĻžāϰāĻĒāĻŋāϏ āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
ā§Ģ. āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
Investigation Plan
- CBC with platelet count.
- Quantitative RPR/VDRL.
- Treponemal assay (TPPA/EIA).
- HSV-1/HSV-2 PCR from lesion, if available.
- HIV Ag/Ab test.
- Glucose/HbA1c if clinically indicated.
- Additional testing according to lesion findings.
Rx Decision
Definitive antimicrobial regimen: To be determined after appropriate clinical assessment and diagnostic evaluation.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻā§āώāϤ āĻĒāϰā§āĻā§āώāĻž āĻ āĻĒā§āϰā§ā§āĻāύā§ā§ āϤāĻĨā§āϝ āϏāĻāĻā§āϰāĻšā§āϰ āĻĒāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ āĻŦāĻž āĻ ā§āϝāĻžāύā§āĻāĻŋāĻāĻžāĻāϰāĻžāϞ āĻāĻŋāĻāĻŋā§āϏāĻž āĻ āĻŋāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Existing linezolid therapy requires prescriber review; this case note does not authorize independent discontinuation or substitution.
Advice
Maintain gentle local hygiene â āĻā§āώāϤāϏā§āĻĨāĻžāύ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āϰāĻžāĻāĻžāĨ¤
Avoid irritating topical products â āĻ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻā§āϰāĻŋāĻŽ āĻŦāĻž āϰāĻžāϏāĻžā§āύāĻŋāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻž āĻāϰāĻžāĨ¤
Avoid sexual contact pending appropriate evaluation and treatment â āĻāĻŋāĻāĻŋā§āϏāĻž āĻ āĻŽā§āϞā§āϝāĻžā§āύ āĻļā§āώ āύāĻž āĻšāĻā§āĻž āĻĒāϰā§āϝāύā§āϤ āϝā§āύāϏāĻŽā§āĻĒāϰā§āĻ āĻā§āĻžāύā§āĨ¤
Follow up promptly â āĻĻā§āϰā§āϤ āĻĢāϞā§āĻāĻĒāĨ¤
Seek urgent care for red flags â āĻŦāĻŋāĻĒāĻā§āĻāύāĻ āϞāĻā§āώāĻŖ āĻĻā§āĻāĻž āĻĻāĻŋāϞ⧠āĻāϰā§āϰāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
Demo clinical note confidence: 0.99 for accurate representation of available data and uncertainty.
đ§ SECTION 16. SPECIALIST REFERRAL
Primary Referral
Dermatologist / Dermatovenereologist â āĻāϰā§āĻŽ āĻ āϝā§āύāϰā§āĻ āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
Reason: Genital ulcer with skin rash and possible STI.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§ āĻāĻž āĻ āĻļāϰā§āϰ⧠āϰâā§āϝāĻžāĻļā§āϰ āĻāĻžāϰāĻŖ āύāĻŋāϰā§āĻŖā§ā§ āĻāϰā§āĻŽ āĻ āϝā§āύāϰā§āĻ āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.99.
Additional Referral
Infectious Disease Specialist â āϏāĻāĻā§āϰāĻžāĻŽāĻ āϰā§āĻ āĻŦāĻŋāĻļā§āώāĻā§āĻ: Complex STI, treatment failure or confirmed coinfection.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻŋāϞ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻāύā§āύāϤāĻŋ āύāĻž āĻšāϞā§āĨ¤
Urologist â āĻāĻāϰā§āϞāĻāĻŋāϏā§āĻ: Persistent suspicious penile lesion or urinary complication.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻāĻž āĻ āĻĨāĻŦāĻž āĻĒā§āϰāϏā§āϰāĻžāĻŦā§āϰ āĻāĻāĻŋāϞāϤāĻž āĻĨāĻžāĻāϞā§āĨ¤
Medicine Specialist â āĻŽā§āĻĄāĻŋāϏāĻŋāύ āĻŦāĻŋāĻļā§āώāĻā§āĻ: Significant unexplained weakness or systemic illness.
āĻŦāĻžāĻāϞāĻž: āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āĻļāĻžāϰā§āϰāĻŋāĻ āϰā§āĻā§āϰ āĻŽā§āϞā§āϝāĻžā§āύā§āĨ¤
Confidence: 0.95.
đŠ SECTION 17. OVERVIEW / SUMMARY
Final Clinical Assessment
The patient presents with physician-documented generalized weakness, genital ulceration and skin rash. The supplied prescription does not contain a definitive diagnosis or laboratory results. Syphilis and genital herpes are important differential diagnoses, while secondary bacterial infection remains possible but unconfirmed.
āĻŦāĻžāĻāϞāĻž āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ
āϰā§āĻā§āϰ āϝā§āύāĻžāĻā§āĻā§ āĻāĻž, āĻļāϰā§āϰ⧠āϰâā§āϝāĻžāĻļ āĻāĻŦāĻ āĻĻā§āϰā§āĻŦāϞāϤāĻžāϰ āĻ āĻāĻŋāϝā§āĻ āϰā§ā§āĻā§āĨ¤ āĻāĻŋāĻāĻŋā§āϏāĻ VDRL āĻ CBC āĻĒāϰā§āĻā§āώāĻž āĻĻāĻŋā§ā§āĻā§āύāĨ¤ āĻāĻŋāύā§āϤ⧠āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ Dx āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ āĻā§āύāĻŋāĻāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāĨ¤ āϤāĻŦā§ āĻā§āύā§āĻāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
Linezolid-āĻāϰ āĻŽāϤ⧠āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻā§āϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻāĻŦāĻ āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Final Prescription-Ready Dx
Dx: Undifferentiated Genital Ulcer Disease with Associated Skin Rash â R/O Syphilis and Genital HSV Infection; ?Secondary Bacterial Infection.
Confidence in working syndromic diagnosis: 0.99.
Definitive etiological diagnosis: Pending clinical examination and investigations.
đŠ ACTIONABLE CLINICAL PLAN
1. Immediate priority: Focused genital and skin examination.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻžāĻā§āĻā§āϰ āĻāĻž āĻ āϰâā§āϝāĻžāĻļ āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰā§āĻā§āώāĻžāĨ¤
2. Diagnostic priority: Syphilis serology and appropriate treponemal confirmation; HSV and HIV testing.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§ā§āĻāύā§ā§ STI āĻĒāϰā§āĻā§āώāĻžāĨ¤
3. Medication priority: Review linezolid indication and CBC monitoring.
āĻŦāĻžāĻāϞāĻž: Linezolid-āĻāϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āϝāĻžāĻāĻžāĻāĨ¤
4. Specialist priority: Dermatovenereology referral.
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻŽ āĻ āϝā§āύāϰā§āĻ āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āĻĒāϰāĻžāĻŽāϰā§āĻļāĨ¤
5. Follow-up priority: Review laboratory results, lesion healing and treatment response.
āĻŦāĻžāĻāϞāĻž: āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻ āĻā§āϰāĻāϤāĻŋ āĻ āύā§āϝāĻžā§ā§ āĻĢāϞā§āĻāĻĒāĨ¤
Overall confidence: 0.98.
đ§ REFERENCE LIST
A. Medical Textbooks
1. Harrison’s Principles of Internal Medicine. 21st edition. McGraw Hill; 2022.
Relevant topics: Syphilis, herpesvirus infections and infectious disease evaluation.
2. Davidson’s Principles and Practice of Medicine. 24th edition. Elsevier; 2022.
Relevant topics: Sexually transmitted infections, skin disease and systemic infection.
3. Andrews’ Diseases of the Skin: Clinical Dermatology. 14th edition. Elsevier; 2024.
Relevant topics: Genital dermatoses, bacterial skin infections and dermatological diagnosis.
4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th edition. McGraw Hill; 2022.
Relevant topics: Antibacterial agents, antihistamines, PPIs and pharmacological safety.
Note: Exact textbook page numbers have not been independently verified and are therefore not supplied.
B. International Guidelines
5. CDC. Sexually Transmitted Infections Treatment Guidelines. 2021.
Genital ulcer disease, syphilis and genital herpes.
CDC â Genital Ulcer Disease Guidelines
6. WHO. Guidelines for the Management of Symptomatic Sexually Transmitted Infections. 2021.
WHO â STI Management Guidelines
7. CDC. Laboratory Recommendations for Syphilis Testing, United States. 2024.
CDC â Syphilis Laboratory Testing Recommendations
8. NIH. Syphilis: Adult and Adolescent Opportunistic Infection Guidelines. Updated 27 May 2026.
9. IDSA. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections. 2014.
IDSA â Skin and Soft Tissue Infection Guideline
C. Peer-Reviewed Journals with Verified DOI
10. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1â187.
DOI: 10.15585/mmwr.rr7004a1
11. Papp JR, Park IU, Fakile Y, et al. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recommendations and Reports. 2024;73(1):1â32.
DOI: 10.15585/mmwr.rr7301a1
12. Hook EW III. Syphilis. The Lancet. 2017;389(10078):1550â1557.
DOI: 10.1016/S0140-6736(16)32411-4
13. Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by IDSA. Clinical Infectious Diseases. 2014;59(2):e10âe52.
DOI: 10.1093/cid/ciu296
D. Bangladesh Drug Reference
MedEx Bangladesh â medex.com.bd
Drug-specific MedEx links are provided separately under each of the six prescribed medicines.
đŠ FINAL AUTHOR & PUBLICATION INFORMATION
Author Name: Md.Rafiqul Islam Lipu
Publication Date: Monday, 2 November 2026
āĻŦāĻžāĻāϞāĻž: āϏā§āĻŽāĻŦāĻžāϰ, ⧍ āύāĻā§āĻŽā§āĻŦāϰ ⧍ā§Ļ⧍ā§ŦāĨ¤
Time Verified: 1:24 PM, Bangladesh Standard Time (UTC+06:00)
Website: raiyyantahsan.com
Department: Dermatology & Venereology
Proposed TC Number: 1485
DCS: 02
Proposed Dermatology Department Case Number: 106
Article Type: Full Bilingual Clinical Case Analysis.
Content: 1 Prescription + 0 Reports + 0 Clinical Images.
Drug Review: 6 Individual Medicines à 17 Parameters = 102 Medicine Review Parameters.
Clinical Decision-Making Modules: 10 Complete Modules.
Article Size: Extended bilingual article, approximately 5,000â6,500 words. This is an editorial estimate rather than an automated count.
Publication Status: Draft â not yet published.
Clinical Disclaimer: This is a prescription-based clinical review and educational working assessment. The exact disease cause is not established without appropriate clinical examination and investigations.